

## Independent Auditor's Report

**To the Members of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**

### Report on the Audit of the Financial Statements

#### Opinion

We have audited the financial statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) (the "Company") which comprise the balance sheet as at 31 March 2025, and the statement of profit and loss (including other comprehensive income), statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2025, and its profit and other comprehensive loss, changes in equity and its cash flows for the year ended on that date.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

#### Management's and Board of Directors' Responsibilities for the Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the state of affairs, profit and other comprehensive loss, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Registered Office:

B S R & Co (a partnership firm with Registration No. BA61223) converted into B S R & Co LLP (a Limited Liability Partnership with LLP Registration No. AAB-8161) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

**Independent Auditor's Report (Continued)**

**Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
- 2 A. As required by Section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our




**Independent Auditor's Report (Continued)**

**Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**

knowledge and belief were necessary for the purposes of our audit.

- b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters stated in the paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
  - c. The balance sheet, the statement of profit and loss (including other comprehensive income), the statement of changes in equity and the statement of cash flows dealt with by this Report are in agreement with the books of account.
  - d. In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
  - e. On the basis of the written representations received from the directors on 31 March 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164(2) of the Act.
  - f. the modifications relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2A(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
  - g. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- a. The Company has disclosed the impact of pending litigations as at 31 March 2025 on its financial position in its financial statements - Refer Note 33 to the financial statements.
  - b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - d (i) The management has represented that, to the best of their knowledge and belief, as disclosed in the Note 42 (vi) to the financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
  - (ii) The management has represented that, to the best of their knowledge and belief, as disclosed in the Note 42 (vii) to the financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
  - (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above



**Independent Auditor's Report (Continued)**

**Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**

contain any material misstatement.

- e. The Company have neither declared nor paid any dividend during the year.
- f. Based on our examination which included test checks, except for the instances mentioned below, the Company has used accounting softwares for maintaining its books of account which have a feature of audit trail (edit log) facility, and the same has operated throughout the year for all relevant transactions recorded in the respective softwares:

The Company migrated to new accounting software during the year for three hospital units, and the audit trail (edit log) feature was not enabled in the previous accounting software.

The feature of audit trail implemented for related fields/tables was done in a phased manner at the application as well as the database layer of the accounting software relating to Purchase, Inventory, account payable, fixed assets and general ledger and hence was not enabled throughout the year.

Post migration to new software, the feature of audit trail implemented for related fields/tables was done in a phased manner at the database layer of the accounting software relating to revenue, account receivable, inventory, and hence was not enabled throughout the year.

Further, where audit trail (edit log) facility was enabled and operated throughout the year for the respective accounting software, we did not come across any instance of the audit trail feature being tampered with. Additionally, where the audit trail (edit log) facility was enabled in the previous year, the audit trail (edit log) has been preserved by the Company as per the statutory requirements for record retention except for the instances mentioned above.


- C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the Company is not a public company. Accordingly, the provisions of Section 197 of the Act are not applicable to the Company. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.: 101248W/W-100022



**Siddhartha Sharma**

*Partner*

Place: Bengaluru

Membership No.: 118756

Date: 27 May 2025

ICAI UDIN: 25118756BMOFOR6008

**Annexure A to the Independent Auditor's Report on the Financial Statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) for the year ended 31 March 2025**

**(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)**

- (i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment and Right of use assets.
- (B) The Company has maintained proper records showing full particulars of intangible assets.
- (i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favour of the lessee) disclosed in the financial statements are held in the name of the Company.
- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of use assets) or intangible assets or both during the year.
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- (ii) (a) The inventory, has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned any working capital limits in excess of five crore rupees in aggregate from banks and financial institutions on the basis of security of current assets at any point of time of the year. Accordingly, clause 3(ii)(b) of the Order is not applicable to the Company.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has made investments in and granted loans to other parties. The Company has provided security to companies. The Company has not made any investments in, granted any loans to, or stood guarantee to or provided security to firms or limited liability partnerships. The Company has not granted any advances in the nature of loans, secured or unsecured, to any companies, firms, limited liability partnerships, or other parties during the year. Details of the loans granted and securities provided are stated in subclause (a) as below:
  - (a) Based on the audit procedures carried on by us and as per the information and explanations given to us the Company has provided security to companies and provided loan to other parties as below:

**Annexure A to the Independent Auditor's Report on the Financial Statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) for the year ended 31 March 2025 (Continued)**

Particulars	Security (Rs. in crore)	Loans (Rs. in crore)
Aggregate amount during the year		
Ultimate Holding Company*	#	-
Holding Company*	#	-
Fellow Subsidiaries*	#	-
Others	-	0.27
Balance outstanding as at balance sheet date		
Ultimate Holding Company*	#	-
Holding Company*	#	-
Fellow Subsidiaries*	#	-
Others	-	0.17

\*As per Companies Act, 2013

# During the year, the Company along with Ultimate Holding company, Holding company and the fellow subsidiaries has provided security to various lenders with respect to term loans amounting to Rs. 4,663.53 crore taken by the Company, its Holding Company and its fellow subsidiaries. Also, refer note 33.1.4 to the financial statements.

- (b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the investments made, security given during the year and the terms and conditions of the grant of loans provided during the year are not prejudicial to the interest of the Company. Further, the Company has not stood guarantee or given any advance in the nature of loan to any party during the year.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, in our opinion the repayment of principal and payment of interest has been stipulated and the repayments or receipts have been regular. Further, the Company has not given any advance in the nature of loan to any party during the year.
- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given. Further, the Company has not given any advances in the nature of loans to any party during the year.
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted falling due during the year, which has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to same parties.
- (f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment.
- (iv) According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of security given by the Company, in our opinion the

**Annexure A to the Independent Auditor's Report on the Financial Statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) for the year ended 31 March 2025 (Continued)**

provisions of Section 185 of the Companies Act, 2013 have been complied with. Further, there are no investments, loans, guarantees and security in respect of which provisions of section 186 of the Act are applicable.

- (v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.
- (vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of healthcare services provided by it and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete.
- (vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion, the undisputed statutory dues including Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues have been regularly deposited by the Company with the appropriate authorities, though there have been slight delays in a few cases of Professional Tax and Provident Fund.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.

- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, statutory dues relating to Goods and Service Tax and Service Tax which have not been deposited on account of any dispute are as follows:

Name of the statute	Nature of the dues	Amount (Rs. in Crores)	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
Goods and Services Tax Act, 2017	GST (including penalties)	27.13	2017-2022	High Court Kolkata	
Finance Act, 1994	Service tax	1.99	2016-17	Additional Commissioner CGST & CX	

- (viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the

**Annexure A to the Independent Auditor's Report on the Financial Statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) for the year ended 31 March 2025 (Continued)**

Income Tax Act, 1961 as income during the year.

- (ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.
- (c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.
- (d) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.
- (e) The Company does not hold any investment in any subsidiaries, associates or joint ventures (as defined under the Act) during the year ended 31 March 2025. Accordingly, clause 3(ix)(e) is not applicable.
- (f) The Company does not hold any investment in any subsidiaries, associates or joint ventures (as defined under the Act) during the year ended 31 March 2025. Accordingly, clause 3(ix)(f) is not applicable.
- (x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.
- (xi) (a) During the course of our examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
- (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- (xiii) The Company is a private limited company and accordingly the requirements as stipulated by the provisions of Section 177 of the Act are not applicable to the Company. In our opinion and according to the information and explanations given to us and on the basis of our examination of records of the Company, transactions with the related parties are in compliance with Section 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- (b) We have considered the internal audit reports of the Company issued till date for the period under audit.



**Annexure A to the Independent Auditor's Report on the Financial Statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) for the year ended 31 March 2025 (Continued)**

- (xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.
- (xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.
- (b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (d) The Company is not part of any group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016 as amended). Accordingly, the requirements of clause 3(xvi)(d) are not applicable.
- (xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- (xviii) There has been resignation of the statutory auditor during the year. Further, there were no issues, objections or concerns raised by the outgoing auditor.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) The requirements as stipulated by the provisions of Section 135 are not applicable to the Company. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Siddhartha Sharma**

*Partner*

Place: Bengaluru

Date: 27 May 2025

Membership No.: 118756

ICAI UDIN:25118756BMOFOR6008

**Annexure B to the Independent Auditor's Report on the financial statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) for the year ended 31 March 2025**

**Report on the internal financial controls with reference to the aforesaid financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act**

**(Referred to in paragraph 2(A)(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)**

**Opinion**

We have audited the internal financial controls with reference to financial statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) ("the Company") as of 31 March 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2025, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

**Management's and Board of Directors' Responsibilities for Internal Financial Controls**

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

**Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

**Annexure B to the Independent Auditor's Report on the financial statements of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) for the year ended 31 March 2025 (Continued)**

**Meaning of Internal Financial Controls with Reference to Financial Statements**

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

**Inherent Limitations of Internal Financial Controls with Reference to Financial Statements**

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.: 101248W/W-100022



**Siddhartha Sharma**

*Partner*

Place: Bengaluru

Date: 27 May 2025

Membership No.: 118756

ICAI UDIN: 25118756BMOFOR6008

Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)

Balance Sheet as at

		(₹ in crores)	
	Note	March 31, 2025	March 31, 2024
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment	3.1	791.44	813.06
Capital work-in-progress	3.2	4.96	5.37
Right-of-use assets	3.3	269.61	200.58
Other Intangible assets	3.1	31.24	4.62
<b>Financial assets</b>			
Investments	4.1	34.06	29.58
Other financial assets	4.2	21.40	12.39
Deferred tax assets (net)	5	95.79	-
Income tax assets (net)	6	61.18	36.01
Other non-current assets	7	1.35	1.15
		<b>1,311.03</b>	<b>1,102.76</b>
<b>Current assets</b>			
Inventories	8	20.03	18.76
<b>Financial assets</b>			
Investments	9.1	0.04	11.48
Trade receivables	9.2	91.66	100.21
Cash and cash equivalents	9.3	14.01	48.32
Bank balances other than cash and cash equivalents	9.4	8.84	5.36
Loans	9.5	0.17	0.19
Other financial assets	9.6	4.25	3.67
Other current assets	10	4.57	6.46
		<b>143.57</b>	<b>194.45</b>
<b>Total assets</b>		<b>1,454.60</b>	<b>1,297.21</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Equity share capital	11	68.78	68.78
Instruments entirely equity in nature	12	100.00	100.00
Other equity	13	(736.71)	(848.76)
<b>Total equity</b>		<b>(567.93)</b>	<b>(679.98)</b>
<b>Non-current liabilities</b>			
<b>Financial liabilities</b>			
Borrowings	14.1	1,769.73	1,733.46
Lease liabilities	14.2	37.14	13.08
Other financial liabilities	14.3	1.31	1.64
Provisions	15	17.93	14.76
		<b>1,826.11</b>	<b>1,762.94</b>
<b>Current liabilities</b>			
<b>Financial liabilities</b>			
Borrowings	16.1	13.60	-
Lease liabilities	14.2	7.34	2.89
Trade payables	16.2		
- total outstanding dues of micro enterprises and small enterprises and		3.68	4.67
- total outstanding dues of creditors other than micro enterprises and small enterprises		145.99	176.07
Other financial liabilities	16.3	5.92	12.08
Other current liabilities	18	8.71	7.97
Provisions	17	11.18	10.57
		<b>196.42</b>	<b>214.25</b>
<b>Total equity and liabilities</b>		<b>1,454.60</b>	<b>1,297.21</b>
<b>Material accounting policies</b>	2.2		

The accompanying notes are an integral part of these Financial Statements

As per our report of even date attached

For B S R & Co. LLP

Chartered Accountants  
Firm Registration number : 101248W/W - 100022


  
Siddhartha Sharma  
Partner

Membership number: 118756

For and on behalf of the Board of Directors of

Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)

  
Sanjeev Agarwal  
Director  
DIN: 07554053

  
Dr. H. Sudarshan Ballal  
Director  
DIN: 01195055

  
Dolly Prasad  
Company Secretary  
Membership No A49842

Place: Bengaluru  
Date: May 27, 2025

Place: Bengaluru  
Date: May 27, 2025

**Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**  
**Statement of Profit and Loss for the year ended**

	Note	(₹ in crores)	
		March 31, 2025	March 31, 2024
<b>Income</b>			
Revenue from operations (net)	19	1,137.18	1,074.77
Other income	20	5.15	4.69
Finance income	21	1.66	1.03
<b>Total income</b>		<b>1,143.99</b>	<b>1,080.49</b>
<b>Expenses</b>			
Purchase of medical consumables and pharmacy items		290.11	311.44
Changes in inventories of medical consumables and pharmacy items	22	(1.27)	(2.65)
Employee benefits expense	23	171.04	153.94
Finance costs	24	152.88	166.78
Depreciation and amortisation expense	25	76.76	64.76
Other expenses	26	436.31	389.16
<b>Total expenses</b>		<b>1,125.83</b>	<b>1,083.43</b>
<b>Profit/ (loss) before tax</b>		<b>18.16</b>	<b>(2.94)</b>
<b>Tax expense</b>			
Current tax	5	-	0.05
Deferred tax	5	(95.31)	-
<b>Total tax (credit)/ expense</b>		<b>(95.31)</b>	<b>0.05</b>
<b>Profit/ (loss) for the year</b>		<b>113.47</b>	<b>(2.99)</b>
<b>Other comprehensive income (OCI)</b>			
Items that will not be reclassified to profit or loss			
Re-measurement loss of defined benefit plans		(1.90)	(3.20)
Income tax effect on above		0.48	-
<b>OCI for the year (net of tax)</b>		<b>(1.42)</b>	<b>(3.20)</b>
<b>Total comprehensive income / (loss) for the year</b>		<b>112.05</b>	<b>(6.19)</b>
<b>Earnings/ (loss) per equity share [nominal value of share ₹ 10 (March 31, 2024: ₹ 10)]</b>	27		
Basic and diluted (₹)		7.79	(0.21)
<b>Material accounting policies</b>	2.2		

The accompanying notes are an integral part of these Financial Statements

As per our report of even date attached

For B S R & Co. LLP


Chartered Accountants  
 Firm Registration number : 101248W/W - 100022



Siddhartha Sharma  
 Partner  
 Membership number: 118756

For and on behalf of the Board of Directors of

Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)



Sameer Agarwal  
 Director  
 DIN: 07554053



Dr. H. Sudarshan Ballal  
 Director  
 DIN: 01195055



Dolly Prasad  
 Company Secretary  
 Membership No: A49842

Place: Bengaluru  
 Date: May 27, 2025

Place: Bengaluru  
 Date: May 27, 2025

Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)  
Statement of changes in equity for the year ended March 31, 2025

(a) Equity share capital \*

Equity shares of ₹ 10 each, issued, subscribed and fully paid-up

	Nos.	(₹ in crores)
Balance as at April 01, 2023	6,87,82,440	68.78
Change in equity share capital during the year	-	-
Balance as at March 31, 2024	6,87,82,440	68.78
Change in equity share capital during the year	-	-
Balance as at March 31, 2025	6,87,82,440	68.78

\* Also, refer note 11

(b) Instruments entirely in the nature of equity \*\*

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Compulsory Convertible Debenture (CCD)		
1,000 (March 31, 2024: 1,000) CCD of ₹ 10,00,000/-	100.00	100.00
	100.00	100.00

\*\* Also, refer note 12

(c) Other equity \*\*\*

	Reserves and surplus		Total other equity
	Retained earnings	Re-measurement loss of defined benefit plans	
Balance as at April 01, 2023	(898.66)	56.09	(842.57)
(Loss) for the year	(2.99)	-	(2.99)
OCI for the year (net of tax)	-	(3.20)	(3.20)
Balance as at March 31, 2024	(901.65)	52.89	(848.76)
Profit for the year	113.47	-	113.47
OCI for the year (net of tax)	-	(1.42)	(1.42)
Balance as at March 31, 2025	(788.18)	51.47	(736.71)

\*\*\* Also, refer note 13

Note : There are no change in the accounting policies or prior period events during the current year or previous year

Nature and purpose of each reserve:

1. **Retained earnings** - Retained earnings comprises of prior and current year undistributed earnings after tax.
2. **Re-measurement of defined benefit plans** - Represents remeasurement gains / (losses) on defined benefit plans (net of tax).


Material accounting policies, refer note 2.2

The accompanying notes are an integral part of these Financial Statements

As per our report of even date attached


For B S R & Co. LLP

Chartered Accountants  
Firm Registration number : 101248W/W - 100022




Siddhartha Sharma  
Partner  
Membership number: 118756

For and on behalf of the Board of Directors of  
Manipal Hospitals (East) India Private Limited (formerly  
known as AMRI Hospitals Private Limited and AMRI  
Hospitals Limited)



Sameer Agarwal  
Director  
DIN: 07554053



Dr. H. Sudarshan Ballal  
Director  
DIN: 01195055



Dolly Prasad  
Company Secretary  
Membership No: A49842

Place: Bengaluru  
Date: May 27, 2025

Place: Bengaluru  
Date: May 27, 2025

Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)  
Statement of Cash Flow Statement for the year ended

	(₹ in crores)	
	March 31, 2025	March 31, 2024
<b>A. Cash flow from operating activities</b>		
Profit / (loss) before tax	18.16	(2.94)
<b>Adjustments:</b>		
Depreciation and amortisation expense	76.76	64.76
Profit on sale of investments in mutual funds (net)	(0.56)	(0.75)
Fair value gain on financial instruments at FVTPL	(3.04)	(0.05)
Bad debts written off	15.74	0.55
Loss allowance on trade receivables (net)	0.11	6.06
Loss (reversals) / allowance on other receivables (net)	(0.09)	0.40
Liabilities no longer required written back	-	0.38
Gain on sale of property, plant and equipment (net)	(0.10)	-
Gain on lease liability reversal	(0.23)	-
Interest income on income tax refund	-	(3.51)
Finance income	(1.66)	(1.03)
Finance costs	148.76	164.31
Operating profit before working capital changes	<u>253.85</u>	<u>228.18</u>
<b>Movements in Working capital :</b>		
Change in trade receivables	(7.30)	(3.10)
Change in other assets	0.78	(4.35)
Change in inventories	(1.27)	(2.65)
Change in other financial assets and loans	(1.63)	0.59
Change in trade payables	(31.07)	35.43
Change in provisions	0.90	6.70
Change in other liabilities	0.74	(2.71)
Change in other financial liabilities	2.11	0.74
<b>Cash generated from operations</b>	<u>217.11</u>	<u>258.83</u>
Income tax (paid) / refunded (net)	(25.17)	30.70
<b>Net cash generated from operating activities</b>	<u>191.94</u>	<u>289.53</u>
<b>B. Cash flow from investing activities</b>		
Acquisition of property, plant and equipment, intangible assets and right-of-use asset	(125.76)	(20.76)
Proceeds from sale of property, plant and equipment	0.61	-
Purchase of Investments in mutual funds	(111.50)	(212.50)
Proceeds from sale of investments mutual funds	122.06	172.25
Maturity of bank deposits (having original maturity of more than three months)	2.40	58.72
Investment made in bank deposits (having original maturity of more than three months)	(13.54)	(65.78)
Interest received	1.22	0.54
<b>Net cash used in investing activities</b>	<u>(124.51)</u>	<u>(67.53)</u>
<b>C. Cash flow from financing activities</b>		
Payment of lease obligations	(3.52)	(2.83)
Interest paid on lease	(1.95)	(1.04)
Repayment of Inter corporate deposit	(433.95)	-
Proceeds from Inter corporate deposit	415.90	33.30
Repayment of long-term borrowings	(0.08)	(1,742.57)
Proceeds of long-term borrowings	68.00	1,700.00
Interest paid on Inter corporate deposit	(6.18)	-
Interest paid on long-term borrowings	(139.96)	(178.27)
<b>Net cash used in financing activities</b>	<u>(101.74)</u>	<u>(191.41)</u>
<b>Net (decrease) / increase in cash and cash equivalents</b>	<u>(34.31)</u>	<u>30.59</u>
Cash and cash equivalents at the beginning of the year	48.32	17.73
<b>Cash and cash equivalents at the end of the year</b>	<u>14.01</u>	<u>48.32</u>
<b>Components of cash and cash equivalents</b>		
Cash on hand	0.86	0.60
With banks - on current accounts	13.15	47.72
<b>Total cash and cash equivalents</b>	<u>14.01</u>	<u>48.32</u>

Refer note 37 for reconciliation of movement of liabilities to cash flows arising from financing activities

The above Statement of Cash flow has been prepared under the "Indirect Method" as set out in Indian Accounting Standard-7, "Statement of Cash Flows"

The accompanying notes are an integral part of these Financial Statements

As per our report of even date attached

For B S R & Co. LLP

Chartered Accountants  
Firm Registration number : 101248W/W - 100022





Siddhartha Sharma  
Partner  
Membership number: 118756

For and on behalf of the Board of Directors of

Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)

  
Sancher Agarwal  
Director  
DIN: 07554053

  
Dr. H. Sudarshan Ballal  
Director  
DIN: 01195055

  
Dolly Prasad  
Company Secretary  
Membership No: A49842

Place: Bengaluru  
Date: May 27, 2025

Place: Bengaluru  
Date: May 27, 2025

**1 Corporate information**

Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) (the "Company" or "MHEIPL") was incorporated on April 16, 1986. As part of its business activities, the Company operates a network of multispecialty hospitals and diagnostic centres. The registered office of the Company is located P 4&5 CIT Scheme LXXII, Gariahat Road, Block-A, Kolkata-700029.

With effect from February 15, 2024, the name of the Company has been changed from AMRI Hospitals Limited to AMRI Hospitals Private Limited and with effect from May 28, 2024, the name of the Company has been changed from AMRI Hospitals Private Limited to Manipal Hospitals (East) India Private Limited.

**2 Material accounting policies**

**2.1 Basis of preparation of the financial statements**

**(a) Statement of compliance**

The financial statements of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as per the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, notified under section 133 of the Companies Act, 2013 ('Act') and other relevant provisions of the Act.

The financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest crores and decimals thereof, except when otherwise indicated.

These financial statements were approved for issue by the Company's Board of Directors on May 27, 2025.

Details of the material accounting policies are included in note 2.2.

**(b) Going Concern**

During the year ended March 31, 2025, the company has a negative net current assets position of ₹ 52.85 crores and the Company's debt-equity ratio is 3:1.

As at March 31, 2025, the Company has accumulated losses and other comprehensive income of ₹ 736.71 crores, against equity share capital of ₹ 68.78 crores and Compulsory Convertible Debenture of ₹ 100.00 crores.

During the year ended March 31, 2025 the Company's profit after tax is ₹ 113.47 crores and has generated net cash from operating activities of ₹ 191.94 crores.

Based on its business plan, the management plans to expand its hospital services and is confident that the Company will be able to generate sufficient profits and required funds from its operations in the foreseeable future. Further the Company has also received commitment from MHEIPL (ultimate holding company) to provide necessary financial support as and when required.

Accordingly, the Management of the Company continues to prepare the financial statements of the Company on a going concern basis.

**(c) Functional and presentation currency**

These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are in Indian Rupees crores except share data and per share data, unless otherwise stated.

**(d) Basis of measurement**

The financial statements have been prepared on the historical cost basis except for the following items:

Items	Measurement
Certain financial assets and liabilities (refer note 34)	Fair value
Net defined asset / liability	Fair Value of plan asset less present value of defined benefit

**(e) Use of estimates and judgments**

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

**Judgements, Assumptions and estimation uncertainties:**

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is included in the following notes:

**Judgements:**

Note 14.2 - Leases and lease classification;

Note 33 - recognition and measurement of provisions and contingencies; key assumptions about the likelihood and magnitude of an outflow of resources

Note 5- recognition of deferred tax

**Estimates:**

Note 2.2 (b), (c) and (f) - useful life of property, plant and equipment, intangible assets and right of use assets

Note - 15 and 17 - Provisions

Note 9.2 and 9.6 - Impairment of financial assets

Note 31 - Employee benefit plan: key actuarial assumptions

Note 35 - Financial instruments



**(f) Measurement of fair values**

The Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair values is included in the note 34 – financial instruments

**2.2 Summary of material accounting policies**

**(a) Current versus non-current classification**

The Company presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in the normal operating cycle,
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is treated as current when :

- It is expected to be settled in the normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

**(b) Property, plant and equipment**

Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, cost of replacing part of the plant and equipment, borrowing costs if the recognition criteria are met and directly attributable cost of bringing the asset to its location and condition necessary for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in statement of profit and loss as incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for a provision are met.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss when the asset is derecognised.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

Property, plant and equipment under installation or construction as at the balance sheet date is shown as capital work-in-progress and the related advances are shown as capital advances under Non current assets.

Depreciation is calculated on a straight-line basis over the useful lives of the assets as estimated by the management and is as follows:

Category of assets	Useful life as per management	Useful life as per Schedule II
Building	23 - 60 years	60 years
Medical equipments	13 years	10 - 15 years
Electric installation	7 years	10 years
Furniture and fixtures	7 years	10 years
Computers	3 years	3 - 6 years
Vehicles	7 years	6 - 10 years

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (upto) the date on which asset is ready for use (disposed of). Second hand assets are depreciated over the estimated useful life as per technical estimates.



Leasehold land/ leasehold improvements/Leasehold Building are depreciated over the primary lease period or useful life, whichever is shorter, on a straight-line basis.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

The management had estimated, supported by technical advice, the useful life of the category of assets, which are lower than those indicated in Schedule II to the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the asset are likely to be used.

**(c) Intangible assets**

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any.

The useful lives of intangible assets are assessed as either finite or indefinite, where applicable.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset, if any.

Intangible assets with indefinite useful lives, if any, are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in profit or loss as incurred.

A summary of amortization policy applied to the Company's intangible assets is as below:

Category of assets	Useful life as per management
Computer software - application	3 to 5 years

**(d) Impairment of non-financial assets**

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

The Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company's CGU to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long term growth rate is calculated and applied to project future cash flows after the fifth year.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs.

Impairment losses of continuing operations, including impairment of inventories, are recognised in the statement of profit and loss.

For assets, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit and loss.

**(e) Borrowing Costs**

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.



(f) **Leases**

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

**Company as a lessee**

The Company accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any re-measurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. The lease payments shall include fixed payments, variable lease payments, residual value guarantees, exercise price of a purchase option where the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently re-measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and re-measuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Company recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognises any remaining amount of the re-measurement in statement of profit and loss.

The Company has elected not to apply the requirements of Ind AS 116 Leases to short term leases of all assets that have a lease term of 12 months or less, except where it anticipates renewals and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

**Company as a lessor**

At the inception of the lease the Company classifies each of its leases as either an operating lease or a finance lease. The Company recognises lease payments received under operating leases as income on a straight-line basis over the lease term. In case of a finance lease, finance income is recognised over the lease term based on a pattern reflecting a constant periodic rate of return on the lessor's net investment in the lease.

If an arrangement contains lease and non-lease components, the Company applies Ind AS 115 Revenue from contracts with customers to allocate the consideration in the contract.

(g) **Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

**Financial assets**

**Initial recognition and measurement**

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price determined under Ind AS 115. Refer to the accounting policies in section (i) Revenue from contracts with customers.

In order for a financial asset to be classified and measured at amortised cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

The Company's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortised cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows while financial assets classified and measured at fair value through OCI are held within a business model with the objective of both holding to collect contractual cash flows and selling.

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

**Subsequent measurement**

For purposes of subsequent measurement, financial assets are classified in four categories:

- i) Financial assets at amortised cost (debt instruments)
- ii) Financial assets at fair value through other comprehensive income (FVTOCI) with recycling of cumulative gains and losses (debt instruments)
- iii) Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments)
- iv) Financial assets at fair value through profit or loss



#### Financial assets at amortised cost (debt instruments)

A 'financial asset' is measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the profit or loss. The Company's financial assets at amortised cost includes trade receivables. For more information on receivables, refer to Note 9.2.

#### Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the balance sheet at fair value with net changes in fair value recognised in the statement of profit and loss.

This category includes derivative instruments and listed equity investments which the Company had not irrevocably elected to classify at fair value through OCI. Dividends on listed equity investments are recognised in the statement of profit and loss when the right of payment has been established.

#### Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

#### Impairment of financial assets

The Company recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

For trade receivables and other financial assets, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

#### Financial liabilities

##### Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts and derivative financial instruments.

##### Subsequent measurement

For purposes of subsequent measurement, financial liabilities are classified in two categories:

- Financial liabilities at fair value through profit or loss
- Financial liabilities at amortised cost (loans and borrowings)



#### Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.

Gains or losses on liabilities held for trading are recognised in the profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/ losses are not subsequently transferred to P&L. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the statement of profit and loss. The Company has not designated any financial liability as at fair value through profit or loss.

#### Financial liabilities at amortised cost (Loans and borrowings)

This is the category most relevant to the Company. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

This category generally applies to borrowings.

#### Financial guarantee contracts

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined as per impairment requirements of Ind AS 109 and the amount recognised less, when appropriate, the cumulative amount of income recognised in accordance with the principles of Ind AS 115.

#### Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

#### Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

#### (h) Inventories

Inventories of pharmacy items and medical consumables are valued at lower of cost or net realizable value. The comparison of cost and net realisable value is made on an item-by-item basis. Cost of these inventories comprises of all costs of purchase and other costs incurred in bringing the inventories to their present location after adjusting for Goods and Services Tax (GST) wherever applicable, applying the first in first out basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs to be incurred to make the sale. Adequate provision is made for slow moving, non-moving and expired inventory, as determined necessary.

#### (i) Total Income

##### (i) Revenue recognition

Revenue from contracts with customers is recognised as per Ind AS 115, when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

##### Disaggregation of revenue

The Company disaggregates revenue into revenue from rendering hospital services, pharmacy sales and other operating income. The Company believes that this disaggregation best depicts how the nature, amount, timing and uncertainty of Company's revenues and cash flows are affected by industry, market and other economic factors.

##### Operating Income

Revenue from Hospital services is recognised as and when the services are performed, unless significant future uncertainties exists, while revenue from sale of pharmacy items is recognised when the control of the goods have passed to the buyer, usually on delivery of the goods. The Company assesses the distinct performance obligations in the contract and measures to at an amount that reflects the consideration it expects to receive, net of Goods and Services Tax and adjusted for discounts and concessions.



## Contract balances

### Trade receivables

Unbilled revenue represents the Company's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in section (g) Financial instruments – initial recognition and subsequent measurement.

### Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Company has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the Company transfers goods or services to the customer, a contract liability is recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Company performs under the contract.

## (ii) Other income

### Interest Income

For all debt instruments measured at amortised cost, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension) but does not consider the expected credit losses. Interest income is included in finance income in the statement of profit and loss.

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "finance income" in the statement of profit and loss.

## (j) Foreign currencies

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The Company's financial statements are presented in Indian Rupee, which is also the Company's functional and presentation currency.

### Transactions and balances

Foreign currency transactions are recorded on initial recognition in the functional currency using the exchange rate prevailing at the date of the transaction. However, for practical reasons, the Company uses an average rate if the average approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Exchange differences arising on the settlement or translation of monetary items are recognised in the statement of profit and loss.

## (k) Retirement and other employee benefits

### Defined contribution plan

Retirement benefit in the form of Provident Fund and Pension Fund, which are defined contribution schemes. The Company recognizes contribution payable to the schemes as an expense, when an employee renders the related service. The Company has no obligation, other than the contribution payable to the fund.

### Defined benefit plan - gratuity

The Company operates a defined benefit plan for its employees for gratuity. The costs of providing benefits under this plan is determined on the basis of actuarial valuation at each year end using the projected unit credit method.

Remeasurements, comprising of actuarial gains and losses, excluding amounts included in interest on the defined benefit liability, are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to the statement of profit and loss in subsequent periods.

Past service costs are recognised in the statement of profit and loss on the earlier of:

- The date of the plan amendment or curtailment, and
- The date that the Company recognises related restructuring costs

Interest is calculated by applying the discount rate to the net defined benefit liability. The Company recognises the following changes in the defined benefit obligation as an expense in the statement of profit and loss:

- Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements; and
- Interest expense

### Other long-term employee benefits - compensated absences

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. The Company presents the entire leave as a current liability in the balance sheet, since it does not have an unconditional right to defer its settlement beyond 12 months after the reporting date.



(l) Taxes

*Current income tax*

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities in accordance with the Income Tax Act, 1961 enacted in India. The tax rates and tax laws used to compute the amounts are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

*Deferred tax*

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences except:

- where deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit and loss.
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit and loss

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred tax assets relate to the same taxable entity and to the same taxation authority.

(m) Earnings Per Share (EPS)

Basic EPS amounts are calculated by dividing the net profit/(loss) for the year attributable to equity shareholders by the weighted average number of equity shares and number of Compulsory Convertible Shares upon conversion of CCDs outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events such as issue of shares, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit/(loss) for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

(n) Provisions

Provision are recognized when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of profit and loss net off any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

*Decommissioning liability*

The Company records a provision for decommissioning costs to dismantle and remove the leasehold improvements from the leased assets. Decommissioning costs are provided at the present value of expected costs to settle the obligation using estimated cash flows and are recognised as part of the cost of the particular asset. The cash flows are discounted at a current pre-tax rate that reflects the risks specific to the decommissioning liability. The unwinding of the discount is expensed as incurred and recognised in the statement of profit and loss as a finance cost. The estimated future costs of decommissioning are reviewed annually and adjusted as appropriate. Changes in the estimated future costs or in the discount rate applied are added to or deducted from the cost of the asset.

*Onerous contracts*

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.



(o) **Contingent liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements unless the possibility of an outflow of resources embodying economic benefits is remote.

Contingent liabilities and commitments are reviewed by the management at each balance sheet date.

(p) **Cash and cash equivalents**

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

(q) **Segment accounting policies**

The Company prepares its segment information based on its reporting to Chief Operating Decision Maker (refer note 28 on segment reporting).

(r) **Corporate Social Responsibility (CSR) expenditure**

CSR expenditure as per provisions of section 135 of Companies Act, 2013 read with The Companies (Corporate Social Responsibility Policy) Rules, 2014, is charged to the statement of profit and loss as an expense as and when incurred.

(s) **Equity share capital**

Incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

(t) **Cash flow statement**

Cash flows are reported using the indirect method, whereby net profit/ (loss) before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated. Bank overdrafts are classified as part of cash and cash equivalent, as they form an integral part of an entity's cash management.

(u) **New and amended standards**

(i) **Ind AS 117 Insurance Contracts**

The Ministry of corporate Affairs (MCA) notified the Ind AS 117, Insurance Contracts, vide notification dated August 12, 2024, under the Companies (Indian Accounting Standards) Amendment Rules, 2024, which is effective from annual reporting periods beginning on or after April 01, 2024.

Ind AS 117 Insurance Contracts is a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. Ind AS 117 replaces Ind AS 104 Insurance Contracts. Ind AS 117 applies to all types of insurance contracts, regardless of the type of entities that issue them as well as to certain guarantees and financial instruments with discretionary participation features; a few scope exceptions will apply. Ind AS 117 is based on a general model, supplemented by:

- A specific adaptation for contracts with direct participation features (the variable fee approach)
- A simplified approach (the premium allocation approach) mainly for short-duration contracts

The application of Ind AS 117 had no impact on the Financial Statements as the Company has not entered any contracts in the nature of insurance contracts covered under Ind AS 117.

(ii) **Amendment to Ind AS 116 Leases – Lease Liability in a Sale and Leaseback**

The MCA notified the Companies (Indian Accounting Standards) Second Amendment Rules, 2024, which amend Ind AS 116, Leases, with respect to Lease Liability in a Sale and Leaseback.

The amendment specifies the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains.

The amendment is effective for annual reporting periods beginning on or after April 01, 2024 and must be applied retrospectively to sale and leaseback transactions entered into after the date of initial application of Ind AS 116.

The amendment does not have a material impact on the Financial Statements.

(v) **Standards issued but not effective**

(i) **Amendment to Ind AS 21 The Effects of Changes in Foreign Exchange Rates**

On May 07, 2025, The Ministry of Corporate Affairs notified the Companies (Indian Accounting Standards) Amendment Rules, 2025, which amend Ind AS 21 The Effects of Changes in Foreign Exchange Rates, to specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows.

The amendments are effective for annual reporting periods beginning on or after 1 April 2025. When applying the amendments, an entity cannot restate comparative information.

The amendments are not expected to have a material impact on the Financial Statements.



Manjal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)

Notes to the financial statements for the year ended March 31, 2025

3.1 Property, plant and equipment and Intangible assets

(₹ in crores)

	Property, plant and equipment										Other Intangible assets	
	Leasehold Land (Refer note 3.1.2)	Freehold Land (Refer note 3.1.3)	Buildings	Electrical installations	Computers	Medical equipments	Vehicles	Furniture & fixtures	Total	Computer software		
<b>Cost</b>												
At April 01, 2023	56.82	70.61	592.61	162.70	17.82	310.63	0.63	35.78	1,247.60	13.10		
Additions	-	-	0.55	1.22	3.81	12.88	-	2.23	20.69	2.27		
Disposals / adjustments	-	-	-	(9.21)	-	-	-	9.21	-	-		
At March 31, 2024	56.82	70.61	593.16	154.71	21.63	323.51	0.63	47.22	1,268.29	15.37		
Additions	-	-	17.05	6.32	19.47	30.37	1.14	8.43	82.78	33.71		
Disposals / adjustments	-	(42.34)	-	(3.67)	2.11	(3.27)	-	1.08	(46.09)	(0.18)		
At March 31, 2025	56.82	28.27	610.21	157.36	43.21	350.61	1.77	56.73	1,304.98	48.90		
<b>Accumulated depreciation / amortisation</b>												
At April 01, 2023	27.54	-	73.04	88.42	14.91	168.98	0.52	24.72	398.13	8.89		
Charge for the year	0.03	-	14.44	12.83	2.21	22.75	0.06	4.78	57.10	1.86		
Disposals / adjustments	-	-	-	(5.28)	-	-	-	5.28	-	-		
At March 31, 2024	27.57	-	87.48	95.97	17.12	191.73	0.58	34.78	455.23	10.75		
Charge for the year	0.03	-	14.86	12.54	5.99	23.33	0.14	4.91	61.80	6.93		
Disposals / adjustments	-	-	-	(2.98)	2.07	(3.19)	-	0.61	(3.49)	(0.02)		
At March 31, 2025	27.60	-	102.34	105.53	25.18	211.87	0.72	40.30	513.54	17.66		
<b>Net book value</b>												
At March 31, 2024	29.25	70.61	505.68	58.74	4.51	131.78	0.05	12.44	813.06	4.62		
At March 31, 2025	29.22	28.27	507.87	51.83	18.03	138.74	1.05	16.43	791.44	31.24		

Note:

- (3.1.1) Refer note 14.1 for details of Property, plant and equipment provided as security for borrowings.  
(3.1.2) Lease held in perpetuity.  
(3.1.3) The Company signed a Deed of Transfer/Exchange with the West Bengal Housing Infrastructure Development Corporation Limited, a Government of West Bengal Company wherein a parcel of freehold land was exchanged for a leasehold land and the impact of the same has been considered in the Financial Statements.



Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)  
Notes to the financial statements for the year ended March 31, 2025

3.2 Capital work in progress


Particulars	Amount in ₹ in crores)	
	March 31, 2025	March 31, 2024
Opening	5.37	-
Additions	82.37	26.06
Less: Transferred to Property, plant and equipment	(82.78)	(20.69)
Closing	4.96	5.37

(3.2.1) Capital work in progress ageing schedule:

Particulars	Amount in ₹ in crores)			
	Less than 1 year	1-2 years	2-3 years	More than 3 years
Projects in progress	4.96	-	-	-
Projects temporarily suspended	-	-	-	-
Total	4.96	-	-	-

Particulars	Amount in ₹ in crores)			
	Less than 1 year	1-2 years	2-3 years	More than 3 years
Projects in progress	5.37	-	-	-
Projects temporarily suspended	-	-	-	-
Total	5.37	-	-	-

There are no material capital work-in-progress for which the completion is overdue or has exceeded its cost compared to its original budget.  
\* Refer note 14.1 for details of assets provided as security for borrowings.



3.3 Right of use assets

(₹ in crores)

	Land (Refer note 3.1.3)	Building	Electrical installation	Equipments	Total
<b>Cost</b>					
At April 01, 2023	187.79	14.78	-	0.87	203.44
Additions	-	11.71	-	-	11.71
Disposals / adjustments	-	-	-	-	-
<b>At March 31, 2024</b>	<b>187.79</b>	<b>26.49</b>	<b>-</b>	<b>0.87</b>	<b>215.15</b>
Additions	2.22	5.06	9.22	19.59	36.09
Disposals / adjustments	42.34	(3.76)	-	-	38.58
<b>At March 31, 2025</b>	<b>232.35</b>	<b>27.79</b>	<b>9.22</b>	<b>20.46</b>	<b>289.82</b>
<b>Depreciation</b>					
At April 01, 2023	-	8.36	-	0.41	8.77
Charge for the year	2.61	2.89	-	0.30	5.80
Disposals	-	-	-	-	-
<b>At March 31, 2024</b>	<b>2.61</b>	<b>11.25</b>	<b>-</b>	<b>0.71</b>	<b>14.57</b>
Charge for the year	3.24	3.74	0.55	0.50	8.03
Disposals / adjustments	-	(2.39)	-	-	(2.39)
<b>At March 31, 2025</b>	<b>5.85</b>	<b>12.60</b>	<b>0.55</b>	<b>1.21</b>	<b>20.21</b>
<b>Net book value</b>					
At March 31, 2024	185.18	15.24	-	0.16	200.58
<b>At March 31, 2025</b>	<b>226.50</b>	<b>15.19</b>	<b>8.67</b>	<b>19.25</b>	<b>269.61</b>

\* Refer note 14.1 for details of Right of use asset provided as security for borrowings.

(This space has been intentionally left blank)



4 Non-current financial assets

4.1 Investments

Investments at fair value through Profit or Loss

Investments in mutual funds (quoted) \*

Aggregate book value/ market value of quoted investments

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		34.06	29.58
		<u>34.06</u>	<u>29.58</u>

\* Refer note 14.1 for details of Investments provided as security for borrowings

Also, Information about the Company's exposure to credit and market risks, and fair value measurement, is included in Note 34 and 35

4.2 Other financial assets (Unsecured considered good unless otherwise stated)

Margin money deposit with banks (refer note 4.2.1)

Deposits with banks due to mature after twelve months from the reporting date (refer note 4.2.2)

Security deposits

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		12.48	4.03
		6.66	6.23
		2.26	2.13
		<u>21.40</u>	<u>12.39</u>

(4.2.1) Margin money deposits with a carrying amount of ₹ 12.48 crores (March 31, 2024: ₹ 4.03 crores) are subject to charge to secure the performance bank guarantees of the Company.

(4.2.2) Represents Debt Service Reserve Account (DSRA) maintained by the Company with bank amounting to ₹ 6.66 crores (March 31, 2024: ₹ 6.23 crores)

5 Income Taxes

The major components of income tax expense are:

Statement of Profit and loss:

Current income tax:

Current income tax charge

Adjustment of tax relating to previous year

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		-	-
		-	0.05
		<u>-</u>	<u>0.05</u>

Deferred tax: \*

Origination and reversal of temporary differences for the current year

Income tax expense recognised in the statement of profit and loss

		(95.31)	-
		<u>(95.31)</u>	<u>0.05</u>

OCI section

Deferred tax related to items recognised in other comprehensive income during the year

Income tax expense reported in other comprehensive income

		(0.48)	-
		<u>(0.48)</u>	<u>-</u>

\* During the year ended March 31, 2025, the Company recognised Deferred Tax Assets (Net) of ₹ 95.79 crores on unabsorbed depreciation of earlier years given it is probable that taxable profit will be available

Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for the year ended March 31, 2025 and year ended March 31, 2024:

Profit / (loss) before tax

At India's statutory income tax rate of 25.17% (March 31, 2024: 25.17%)

Tax effect of non-deductible expenses

Tax adjustment pertaining to earlier years

Deferred tax recognised basis reasonable certainty

Others

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		18.16	(2.94)
		4.57	(0.74)
		0.94	-
		-	0.05
		(101.39)	-
		0.09	0.74
		<u>(95.79)</u>	<u>0.05</u>

Deferred tax

Property plant equipment, right of use assets and intangible assets: Impact of difference between tax depreciation as per Income Tax Act, 1961 over depreciation/ amortization as per Companies Act, 2013

Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis \*\*

Provision for doubtful debts and advances

Deferred tax on fair valuation of investments in mutual funds

Unabsorbed depreciation

Deferred tax assets not recognised in earlier years, recognised in current year basis reasonable certainty

		(₹ in crores)			
		Recognised in balance sheet		Recognised in profit and loss and other comprehensive income	
		March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
		(66.16)	(54.56)	11.60	54.56
		20.83	11.60	(9.23)	(11.60)
		2.88	2.88	-	(2.88)
		(0.78)	(0.01)	0.77	0.01
		139.02	143.33	4.31	(143.33)
		-	(103.24)	(103.24)	103.24
		<u>95.79</u>	<u>-</u>	<u>(95.79)</u>	<u>-</u>

\* Includes items under 43B such as Leave encashment, gratuity and bonus

# Gratuity amount routed through Other Comprehensive Income pertaining to remeasurement of defined benefit plan

Reflected in the balance sheet as follows:

Deferred tax assets

Deferred tax liabilities

Net deferred tax assets

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		162.73	157.81
		(66.94)	(157.81)
		<u>95.79</u>	<u>-</u>

Reconciliation of deferred tax assets

Opening balance

Tax credit during the year recognised in profit and loss

Tax credit during the year recognised in OCI

Net deferred tax assets

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		-	-
		95.31	-
		0.48	-
		<u>95.79</u>	<u>-</u>



**Unrecognised deferred tax asset:**

Deferred tax assets have not been recognised in respect of the following items, because it is not probable that future taxable profit will be available against which the Company can use the benefits therefrom

	March 31, 2025		March 31, 2024	
	Gross amount	Unrecognised Tax effect	Gross amount	Unrecognised Tax effect
Carried forward business losses	-	-	-	-
Carried forward unabsorbed depreciation	-	-	569.48	143.33
	-	-	569.48	143.33

**Tax losses carried forward:**

Tax losses for which no deferred tax asset was recognised expire as follows:

	March 31, 2025		March 31, 2024	
	Amount (in Crores)	Expiry date	Amount (in Crores)	Expiry date
Carried forward unabsorbed depreciation	-	-	569.48	Not Applicable

During the year ended March 31, 2024, upon sale of agreed shares, the persons holding more than 51% of the beneficial ownership of voting power of the Company changed and thus as per Section 79 of Income Tax Act 1961, carry forward and set off business losses of any preceding financial year in which the share holding pattern changed, were lapsed

**6 Income tax assets (net)**

Income tax assets (net of provision for income tax)

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		61.18	36.01
		61.18	36.01

**7 Other non-current assets (Unsecured, considered good unless otherwise stated)**

Disputed capital advances  
Balances with statutory/ government authorities  
Prepaid expenses

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		0.74	0.74
		0.59	0.40
		0.02	0.01
		1.35	1.15

**8 Inventories (valued at lower of cost and net realizable value)**

Medical consumables  
Pharmacy items

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		9.42	5.30
		10.61	13.46
		20.03	18.76

\* Refer note 14.1 for details of Inventories provided as security for borrowings

**9 Current financial assets**

**9.1 Investments**

Investments at fair value through Profit and Loss

Investments in mutual funds (quoted) \*

Aggregate book value/market value of quoted investments

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		0.04	11.48
		0.04	11.48

\* Information about the Company's exposure to credit and market risks, and fair value measurement, is included in Note 34 and 35

\* Refer note 14.1 for details of Investments provided as security for borrowings

**9.2 Trade receivables (Unsecured, considered good unless otherwise stated)**

Considered good  
Credit impaired

Less: loss allowance on trade receivables

		(₹ in crores)	
		March 31, 2025	March 31, 2024
		91.66	100.21
		11.11	11.00
		102.77	111.21
		(11.11)	(11.00)
		91.66	100.21

(9.2.1) Refer note 14.1 for details of trade receivables provided as security for borrowings

(9.2.2) There are no trade receivables which have significant increase in credit risk

(9.2.3) Ageing for trade receivables from the due date of payment for each of the category is as follows:

As at March 31, 2025

Particulars	Outstanding for following periods from due date of payment						Total
	Not due (including unbilled revenue) *	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade Receivables - considered good	59.51	29.28	2.87	-	-	-	91.66
Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed Trade receivable - credit impaired	0.14	0.52	9.93	0.52	-	-	11.11
Disputed Trade receivables - considered good	-	-	-	-	-	-	-
Disputed Trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed Trade receivables - credit impaired	-	-	-	-	-	-	-
<b>Total</b>	<b>59.65</b>	<b>29.80</b>	<b>12.80</b>	<b>0.52</b>	<b>-</b>	<b>-</b>	<b>102.77</b>



As at March 31, 2024		Outstanding for following periods from due date of payment						(₹ in crores)
Particulars	Not due (including unbilled revenue) *	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total	
								Undisputed Trade Receivables - considered good
Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-	
Undisputed Trade receivable - credit impaired	2.10	1.66	2.38	1.80	1.96	1.10	11.00	
Disputed Trade receivables - considered good	-	-	-	-	-	-	-	
Disputed Trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-	
Disputed Trade receivables - credit impaired	-	-	-	-	-	-	-	
<b>Total</b>	<b>65.80</b>	<b>26.01</b>	<b>10.21</b>	<b>5.64</b>	<b>2.45</b>	<b>1.10</b>	<b>111.21</b>	

\* includes unbilled revenue of ₹ 9.60 crores (March 31, 2024: ₹ 9.99 crores)

9.3 Cash and cash equivalents

Balances with banks:  
- On current accounts  
Cash on hand

(₹ in crores)	
March 31, 2025	March 31, 2024
13.15	47.72
0.86	0.60
<b>14.01</b>	<b>48.32</b>

9.4 Bank balances other than cash and cash equivalents

Deposits with banks original maturity with more than three months but less than twelve months

(₹ in crores)	
March 31, 2025	March 31, 2024
8.84	5.36
<b>8.84</b>	<b>5.36</b>

9.5 Loans (Unsecured, considered good unless otherwise stated)

Loans to employees (refer note 9.5.1)

(9.5.1) There are no loans which have significant increase in credit risk nor which are credit impaired

(₹ in crores)	
March 31, 2025	March 31, 2024
0.17	0.19
<b>0.17</b>	<b>0.19</b>

9.6 Other financial assets (Unsecured, considered good unless otherwise stated)

Interest accrued on fixed deposits with banks  
Security deposits  
Margin money deposit with banks (refer note 9.6.1)  
Other receivables (includes receivable from a related party, refer note 30)  
Considered good  
Credit impaired  
Less: loss allowance on other receivables

(₹ in crores)	
March 31, 2025	March 31, 2024
0.77	0.41
0.24	0.24
1.12	2.34
2.12	0.68
0.35	0.44
(0.35)	(0.44)
<b>2.12</b>	<b>0.68</b>
<b>4.25</b>	<b>3.67</b>

(9.6.1) Margin money deposits with a carrying amount of ₹ 1.12 crores (March 31, 2024: ₹ 2.34 crores) are subject to charge to secure the performance bank guarantees of the Company.

\* Refer note 14.1 for details of Other financial assets provided as security for borrowings

10 Other current assets (Unsecured, considered good unless otherwise stated)

Capital advances  
Prepaid expenses  
Balances with statutory/ government authorities  
Advances to suppliers

(₹ in crores)	
March 31, 2025	March 31, 2024
-	0.91
2.50	0.96
1.16	1.33
0.91	3.26
<b>4.57</b>	<b>6.46</b>

\* Refer note 14.1 for details of Other assets provided as security for borrowings

(This space has been intentionally left blank)



11 Share capital

	(₹ in crores)	
	March 31, 2025	March 31, 2024
11.1 Authorised shares (Nos.) 150,000,000 (March 31, 2024: 150,000,000) equity shares of ₹ 10/- each	150.00	150.00
11.2 Issued, subscribed and fully paid-up shares (Nos.) 68,782,440 (March 31, 2024: 68,782,440) equity shares of ₹ 10/- each, Total issued, subscribed and fully paid-up share capital	68.78 68.78	68.78 68.78

(i) On September 20, 2023 Manipal Hospitals Private Limited ("MHPL") along with its affiliates and nominees acquired 5,71,12,194 equity shares and 850 compulsorily convertible debentures of the Company from existing shareholders aggregating to 84.07% shareholding of the Company on a fully diluted basis. Consequently, the Company is a subsidiary of MHPL and step down subsidiary of MHEPL.

11.3 Reconciliation of the number of equity shares outstanding at the beginning and at the end of the reporting year:

	March 31, 2025		March 31, 2024	
	(Nos.)	(₹ in crores)	(Nos.)	(₹ in crores)
At the beginning of the year	6,87,82,440	68.78	6,87,82,440	68.78
Add: Issued during the year	-	-	-	-
At the end of the year	6,87,82,440	68.78	6,87,82,440	68.78

11.4 Terms/rights attached to equity shares

The Company has only one class of equity shares having par value of ₹ 10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. The final dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. During the year, the Company has not declared any dividend.

In the event of liquidation of the Company, the holders of equity shares would be entitled to receive remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to number of equity shares held by shareholders.

11.5 Shares held by holding company

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Manipal Hospitals Private Limited 57,112,194 (March 31, 2024: 57,112,194) equity shares of ₹ 10/- each, *	57.11	57.11

\* Includes 5 (March 31, 2024: 5) equity shares of ₹ 10 each held by its affiliates and nominees on behalf of the holding company.

11.6 Details of shareholders holding more than 5% shares in the Company:

	March 31, 2025		March 31, 2024	
	(Nos.)	(%)	(Nos.)	(%)
Manipal Hospitals Private Limited (including shares held by its affiliates and nominees)	5,71,12,194	83.03%	5,71,12,194	83.03%
PAN Emami Cosmed Limited (formerly known as "Midkot Investments Private Limited")	47,62,502	6.92%	47,62,502	6.92%

As per the records of the Company, including its register of shareholders/ members and other declaration received from shareholders regarding beneficial interest, the above shareholding represent beneficial ownership of shares.

11.7 Details of shareholding by the promoters of the company

As at March 31, 2025

Promoter Name	No. of shares at the beginning of the year	Change during the year	No. of shares at the end of the year	% of Total Shares	% change during the year
Equity shares of ₹10 each fully paid up held by:					
Manipal Hospitals Private Limited	5,71,12,194	-	5,71,12,194	83.03%	-
	5,71,12,194	-	5,71,12,194	83.03%	-



As at March 31, 2024 #

Promoter Name	No. of shares at the beginning of the year	Change during the year	No. of shares at the end of the year	% of Total Shares	% change during the year
<b>Equity shares of ₹10 each fully paid up held by:</b>					
Manipal Hospitals Private Limited	-	5,71,12,194	5,71,12,194	83.03%	100%
PAN Emami Cosmed Limited (formerly known as "Midkot	47,62,502	(47,62,502)	-	-	(100.00)%
Suraj Finvest Private Limited	1,39,38,600	(1,39,38,600)	-	-	(100.00)%
Diwakar Finvest Private Limited	1,65,75,330	(1,65,75,330)	-	-	(100.00)%
(Previously Known As Sneha Enclave Private Limited)	-	-	-	-	(100.00)%
Radheshyam Agarwal	18,30,000	(18,30,000)	-	-	(100.00)%
Aditya Vardhan Agarwal	5,03,315	(5,03,315)	-	-	(100.00)%
Harsha Vardhan Agarwal	16,51,414	(16,51,414)	-	-	(100.00)%
Mohan Goenka	2,66,170	(2,66,170)	-	-	(100.00)%
Rajkumar Goenka	30,70,120	(30,70,120)	-	-	(100.00)%
Ashish Goenka	10,000	(10,000)	-	-	(100.00)%
Saroj Goenka	3,00,000	(3,00,000)	-	-	(100.00)%
Santosh Goenka	30,68,452	(30,68,452)	-	-	(100.00)%
Indu Goenka	28,15,120	(28,15,120)	-	-	(100.00)%
Radheshyam Goenka	16,50,000	(16,50,000)	-	-	(100.00)%
Priti A Sureka	33,71,491	(33,71,491)	-	-	(100.00)%
Manish Goenka	3,60,248	(3,60,248)	-	-	(100.00)%
Usha Agarwal	28,69,550	(28,69,550)	-	-	(100.00)%
Rashmi Goenka	12,73,950	(12,73,950)	-	-	(100.00)%
Prashant Goenka	15,000	(15,000)	-	-	(100.00)%
Jyoti Goenka	17,16,410	(17,16,410)	-	-	(100.00)%
Richa Agarwal	5,65,600	(5,65,600)	-	-	(100.00)%
Saswat Goenka	30,000	(30,000)	-	-	(100.00)%
Vibhash Vardhan Agarwal	12,90,000	(12,90,000)	-	-	(100.00)%
Sushil Kumar Goenka HUF	2,70,000	(2,70,000)	-	-	(100.00)%
Mansi Agarwal	7,07,500	(7,07,500)	-	-	(100.00)%
Mohan Goenka HUF	5,40,000	(5,40,000)	-	-	(100.00)%
Oriental Sales Agencies (India) Pvt Ltd	39,72,120	(39,72,120)	-	-	(100.00)%
Smriti Agarwal	3,334	(3,334)	-	-	(100.00)%
Shobhana Agarwal	3,334	(3,334)	-	-	(100.00)%
	<b>6,74,29,560</b>	<b>(1,03,17,366)</b>	<b>5,71,12,194</b>	<b>83.03%</b>	<b>(15.30)%</b>

# On September 20, 2023, MHPL has acquired 84.07% shareholding interest on a fully diluted basis, post which MHPL is the promoter of the Company

**11.8 Shares allotted for consideration other than cash**

(a) There have been no issue of bonus shares, buy back of shares, issue of shares for consideration other than cash for the period of five years immediately preceding the balance sheet date

**11.9** As at March 31, 2025 and March 31, 2024, the Company does not have any shares reserved for issue under options and contracts or commitments for the sale of shares except for Compulsory Convertible Debentures (refer note 12).

**12 Instruments entirely equity in nature**

	₹ in crores	
	March 31, 2025	March 31, 2024
<b>Compulsory Convertible Debenture (CCD)</b>		
1,000 (March 31, 2024: 1,000) CCD of ₹ 10,00,000/- each	100.00	100.00
	<b>100.00</b>	<b>100.00</b>

CCD issued on December 31, 2015 to be converted to 7,69,23,000 Equity Shares on or before 10 Years from date of allotment at ₹ 13/- Per Share and such terms can be amended by mutual consent. The CCD shall rank pari passu to the existing Equity Shares after conversion. Also refer note 30

**Details of shareholders holding more than 5% CCD in the Company:**

	March 31, 2025		March 31, 2024	
	(Nos.)	(%)	(Nos.)	(%)
Manipal Hospitals Private Limited	850	85.00%	850	85.00%
PAN Emami Cosmed Limited (formerly known as "Midkot Investments Private Limited")	150	15.00%	150	15.00%

**13 Other equity**

	₹ in crores	
	March 31, 2025	March 31, 2024
<b>13.1 Retained earnings</b>		
Balance at the beginning of the year	(901.65)	(898.66)
Add: Profit / (loss) for the year	113.47	(2.99)
<b>Balance at the end of the year</b>	<b>(788.18)</b>	<b>(901.65)</b>
<b>13.2 Re-measurement loss of defined benefit plans</b>		
Balance at the beginning of the year	52.89	56.09
Add: OCI for the year (net of tax)	(1.42)	(3.20)
<b>Balance at the end of the year</b>	<b>51.47</b>	<b>52.89</b>
<b>Total of other equity</b>	<b>(736.71)</b>	<b>(848.76)</b>



14 Non-current financial liabilities

14.1 Borrowings

	(₹ in crores)	
	March 31, 2025	March 31, 2024
<b>Non-current Borrowings</b>		
Term loan from banks (secured) (refer note 14.1.1 to 14.1.2)	1,700.00	1,700.00
Term loan from financial institutions (secured) (refer note 14.1.1 to 14.1.2)	67.92	-
Inter-corporate deposits ('ICD') (unsecured) (refer note 14.1.3 and 14.1.4)	15.41	33.46
	1,783.33	1,733.46
<b>Less: Current maturities - disclosed under the head short term borrowings</b>		
Term loan from banks	13.00	-
Term loan from financial institutions	0.60	-
	1,769.73	1,733.46

14.1.1 Details of principal outstanding, effective interest rate and repayment terms for borrowings from bank and financial institutions:-

As at March 31, 2025

Particulars	Interest Rate as on March 31, 2025	Frequency	Number of structured installments	Year of Maturity	Principal Outstanding (net of transaction cost)
Secured Term loan (Bank 1)	7.94%	Quarterly	Upto 40 Installments	September 30, 2035	425.00
Secured Term loan (Bank 2)	8.15%	Quarterly	Upto 40 Installments	August 31, 2038	400.00
Secured Term loan (Bank 3)	7.84%	Quarterly	Upto 40 Installments	September 30, 2035	300.00
Secured Term loan (Bank 4)	7.94%	Quarterly	Upto 40 Installments	September 30, 2035	300.00
Secured Term loan (Bank 5)	8.00%	Quarterly	Upto 40 Installments	September 30, 2035	275.00
Secured Term loan (Financial institution 1)	8.25%	Quarterly	Upto 80 Installments	December 31, 2044	67.92
<b>Total</b>					1,767.92

As at March 31, 2024

Particulars	Interest Rate as on March 31, 2024	Frequency	Number of structured installments	Year of Maturity	Principal Outstanding (net of transaction cost)
Secured Term loan (Bank 1)	8.35%	Quarterly	Upto 40 Installments	September 30, 2035	425.00
Secured Term loan (Bank 2)	8.40%	Quarterly	Upto 40 Installments	August 31, 2038	400.00
Secured Term loan (Bank 3)	8.22%	Quarterly	Upto 40 Installments	September 30, 2035	300.00
Secured Term loan (Bank 4)	8.32%	Quarterly	Upto 40 Installments	September 30, 2035	300.00
Secured Term loan (Bank 5)	8.25%	Quarterly	Upto 40 Installments	September 30, 2035	275.00
<b>Total</b>					1,700.00

14.1.2 The terms and conditions of all the term loans from banks and financial institutions are similar and are as follows:

During the year ended March 31, 2025, the Company entered into facility agreement with its lenders and offered consolidated security as below:-

- first ranking pari passu Security Interest over all movable fixed assets and current assets of the Company, MHEPL, Manipal Hospitals (Dwarka) Private Limited ('MHDPL'), Manipal Hospitals (Bengaluru) Private Limited ('MHBPL') & MHPL including but not limited to movable plant and machinery, machinery spares, tools and accessories, furniture, fixtures, intangible assets (including goodwill, trademarks and patents) and all other movable properties of whatsoever nature (both present and future) (other than any debt service reserve amounts (including in the form of fixed deposits or lien marked mutual funds) or debt service reserve accounts required to be maintained or maintained with respect to the Facilities) as per the facility agreement;
- first ranking pari passu Security Interest over specific Immovable Properties of the Company, MHEPL, MHDPL, & MHPL
- first ranking pari passu Security Interest, by way of hypothecation, over all leasehold improvements of all Immovable Properties and Excluded Properties.
- exclusive Security Interest over the debt service reserve amounts (including in the form of fixed deposits or lien marked mutual funds) or debt service reserve accounts required to be maintained or maintained with respect to such Facility)

During the year ended March 31, 2024, MHPL acquired the Company and refinanced existing bank debts and promoter debts of MHEPL. The Company entered into facility agreements with Axis bank, HDFC bank, Canara bank, Indus Ind bank and Kotak bank and offered consolidated security as below:-

- A first pari-passu charge over all movable, immovable fixed assets and current assets of the Company along with Manipal Health Enterprises Private Limited (MHEPL), Manipal Hospitals Private Limited (MHPL), Manipal Hospitals (Bengaluru) Private Limited (MHBPL) & Manipal Hospitals (Dwarka) Private Limited (MHDPL) other than fixed Deposits and mutual funds kept as DSRA & immovable properties mentioned as excluded properties in facility agreements.
- Exclusive security interest over the amount in the Debt Service Reserve Accounts required to be maintained by MHEPL.

14.1.3 Details of principal outstanding, effective interest rate and repayment terms for inter-corporate deposits (refer note 30)-

	March 31, 2025	March 31, 2024
Principal outstanding (₹ in crores)	15.41	33.46
Effective Interest Rate	9.00%	9.00%
Repayment Terms	2026 & 2027	2026

14.1.4 Inter-corporate deposits received from Manipal Hospitals Private Limited ('MHPL'), Manipal Hospitals Synergie Private Limited ('MHSPL') and the interest accrued on the same, also refer note 14.3 and 30

<u>Entities</u>	March 31, 2025	March 31, 2024
Manipal Hospitals Private Limited - 'MHPL'		
Principal	12.41	33.46
Interest accrued	0.35	1.46
Manipal Hospitals Synergie Private Limited - 'MHSPL'		
Principal	3.00	-
Interest accrued	0.81	-



14.2 Lease liability	(₹ in crores)	
	March 31, 2025	March 31, 2024
Opening balance	15.97	7.31
Add: New leases during the year	33.62	11.49
Add: Interest accrued	1.95	1.04
Less: Interest paid	(1.95)	(1.04)
Less: Lease payments	(3.52)	(2.83)
Less: Lease liability reversed	(1.59)	-
	<u>44.48</u>	<u>15.97</u>
Non-current	37.14	13.08
Current	7.34	2.89

- 14.2.1 Notes**  
Refer notes 2.2(f) in relation to accounting policy for leases and treatment on transition  
Refer note 3.3 for depreciation charge for right-of-use assets by class of underlying asset and additions to right-of-use assets and the carrying amount of right-of-use assets at the end of the reporting period by class of underlying asset  
Refer note 26.1 in relation to short term leases and leases of low-value assets accounted for applying paragraph 6 of Ind AS 116  
The Company has taken on lease certain building for hospital operations, hostels for staff, equipments and office spaces and certain software for use in the course of its business  
Refer note 35 (c) disclosure on maturity analysis of lease payments  
Refer note 37 disclosure on cash outflows for lease liabilities

14.3 Other financial liabilities	(₹ in crores)	
	March 31, 2025	March 31, 2024
Interest accrued on Inter-corporate deposit	1.16	1.46
Security deposits received	0.15	0.18
	<u>1.31</u>	<u>1.64</u>

15 Provisions	(₹ in crores)	
	March 31, 2025	March 31, 2024
Non-current		
Provision for gratuity (refer note 31)	17.93	14.76
	<u>17.93</u>	<u>14.76</u>

16 Current financial liabilities	(₹ in crores)	
	March 31, 2025	March 31, 2024
16.1 Borrowings		
Current maturities of long-term borrowings (refer note 14.1)	13.60	-
	<u>13.60</u>	<u>-</u>

16.2 Trade payables	(₹ in crores)	
	March 31, 2025	March 31, 2024
Trade payables		
- total outstanding dues of micro enterprises and small enterprises [refer note 38]	3.68	4.67
- total outstanding dues of creditors other than micro enterprises and small enterprises	145.99	176.07
	<u>149.67</u>	<u>180.74</u>

(16.2.1) Ageing for trade payables from the due date of payment for each of the category mentioned above:

As at March 31, 2025	(₹ in crores)					
	Particulars	Outstanding for following periods from due date of payment				
Not due #		Less than 1 year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	3.62	0.06	-	-	-	3.68
Total outstanding dues of creditors other than micro enterprises and small enterprises	128.67	14.59	2.34	0.39	-	145.99
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
<b>Total</b>	<b>132.29</b>	<b>14.65</b>	<b>2.34</b>	<b>0.39</b>	<b>-</b>	<b>149.67</b>



Particulars	Outstanding for following periods from due date of payment					
	Not due #	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Total outstanding dues of micro enterprises and small enterprises	3.65	0.90	0.12	-	-	4.67
Total outstanding dues of creditors other than micro enterprises and small enterprises	127.37	47.99	0.43	0.28	-	176.07
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
<b>Total</b>	<b>131.02</b>	<b>48.89</b>	<b>0.55</b>	<b>0.28</b>	<b>-</b>	<b>180.74</b>

# Including Provision for expense

(16.2.2) There were no disputed dues to Micro enterprises and small enterprises and other creditors.

16.3 Other financial liabilities

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Capital creditors [refer note (16.3.1)]	2.91	11.20
Interest accrued but not due on borrowings from banks	0.15	0.16
Retention money	1.49	0.28
Sundry deposit	0.06	-
Other payables (includes payable to related party, refer note 30)	1.31	0.44
	<b>5.92</b>	<b>12.08</b>

(16.3.1) As at March 31, 2025, outstanding amount of ₹ 0.42 (March 31, 2024: ₹ 0.37 crores), is due to micro and small enterprises. There are no interest due or outstanding on the same. There were no amounts paid to micro and small enterprises beyond the appointed date during the current and the previous years.

17 Provisions

	(₹ in crores)	
	March 31, 2025	March 31, 2024
<b>Current</b>		
Provision for compensated absences	11.18	10.57
	<b>11.18</b>	<b>10.57</b>

18 Other current liabilities

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Statutory dues	6.35	6.09
Advance received from customers (refer note 19 (b))	0.74	0.21
Other liabilities	1.62	1.67
	<b>8.71</b>	<b>7.97</b>

(This space has been intentionally left blank)



19	Revenue from operations (net)	(₹ in crores)	
		March 31, 2025	March 31, 2024
	Hospital services	1,158.91	1,142.57
	Pharmacy sales	17.52	0.22
	Less: Discounts	(47.17)	(75.14)
	<b>Total (a)</b>	<b>1,129.26</b>	<b>1,067.65</b>
	<b>Other operating income</b>		
	Rental income	1.55	1.27
	Others	6.37	5.85
	<b>Total (b)</b>	<b>7.92</b>	<b>7.12</b>
	<b>Total (a+b)</b>	<b>1,137.18</b>	<b>1,074.77</b>

- a) The revenue from contracts with customer at disaggregation is provided above.  
b) Changes in contract liabilities- Advance from customers

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Balance at the beginning of the year	0.21	0.24
Less: Revenue recognised that was included in the balance at the beginning of the year	(0.21)	(0.24)
Add: Increase due to advance from customer received	0.74	0.21
<b>Balance at the end of the year</b>	<b>0.74</b>	<b>0.21</b>
<b>Expected revenue recognition from remaining performance obligations:</b>		
- Within one year	0.74	0.21

The aforesaid is expected to be recognised as revenue within one year

- c) Contract balances

	(₹ in crores)	
	March 31, 2025	March 31, 2024
<i>Receivables</i>		
- Trade receivables	91.66	100.21
<i>Contract liabilities</i>		
- Advance from customers	0.74	0.21

Unbilled revenue is relating to the service rendered where the invoicing is not done and Trade receivable are non-interest bearing and are generally on a terms of 30 to 120 days.

Contract liabilities relates to the advances received from the customers to deliver the hospital service. There is no significant changes in the contract liabilities during the year.

- d) The company performance obligation is to provide the health care service to patients, this is part of a contract that has an original expected duration of less than one year, hence the company has taken the practical expedient related to performance obligation disclosure as provided by Ind AS 115.

20	Other income	(₹ in crores)	
		March 31, 2025	March 31, 2024
	Profit on sale of investments in mutual funds (net)	0.56	0.75
	Interest income on income tax refund	1.45	3.51
	Gain on sale of plant, property and equipment (net)	0.10	-
	Liability written back	-	0.38
		<b>5.15</b>	<b>4.69</b>



21 Finance income

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Interest income on financial assets at amortised cost	0.08	0.08
Interest income on fixed deposits with banks	1.58	0.95
	<b>1.66</b>	<b>1.03</b>

22 Changes in inventories of medical consumables and pharmacy items

	(₹ in crores)	
	March 31, 2025	March 31, 2024
<b>Pharmacy items</b>		
Inventory at the beginning of the year	13.46	-
Less: Inventory at the end of the year	(10.61)	(13.46)
(A)	<b>2.85</b>	<b>(13.46)</b>
<b>Other medical consumables</b>		
Inventory at the beginning of the year	5.30	16.11
Less: Inventory at the end of the year	(9.42)	(5.30)
(B)	<b>(4.12)</b>	<b>10.81</b>
<b>Changes in inventories</b>	<b>(A+B) (1.27)</b>	<b>(2.65)</b>

23 Employee benefits expense

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Salaries, wages and bonus	155.38	139.86
Contribution to provident and other funds (refer note 31)	10.74	8.05
Gratuity expense (refer note 31)	2.37	3.64
Staff welfare expenses	2.55	2.39
	<b>171.04</b>	<b>153.94</b>

24 Finance costs

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Bank charges	4.12	2.47
Guarantee commission (refer note 30)	-	1.98
Interest		
- on term loan from banks	139.93	115.41
- on working capital loan	-	1.51
- on Inter-corporate deposit (refer note 30)	5.88	1.62
- on lease liability [refer note 2.2(f)]	1.95	1.04
- on defined benefit obligation (refer note 31)	0.98	0.54
- on long term borrowings from related parties (refer note 30)	-	36.88
- on others	0.02	-
Loan processing fees		
- on financial liabilities measured at amortised cost	-	5.33
<b>Total interest expense</b>	<b>148.76</b>	<b>162.33</b>
	<b>152.88</b>	<b>166.78</b>

25 Depreciation and amortisation expense

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Depreciation of property, plant and equipment (refer note 3.1)	61.80	57.10
Amortization of intangible assets (refer note 3.1)	6.93	1.86
Depreciation of right-of-use assets (refer note 3.3)	8.03	5.80
	<b>76.76</b>	<b>64.76</b>



26 Other expenses

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Doctors professional fees	242.65	235.25
Sub contractor charges	7.26	6.43
House keeping, including consumables	36.42	29.08
Power, fuel and other utilities	19.38	17.73
Security charges	10.39	9.56
Rent (refer note 26.1)	3.98	4.39
Rates and taxes	3.41	1.17
Insurance	2.53	1.19
Repairs and maintenance		
- Buildings	0.90	2.17
- Plant and machinery	16.93	27.50
- Others	19.38	6.01
Directors' sitting fees *	-	0.01
Advertising and sales promotion *	29.35	15.42
Travelling and conveyance	4.81	5.81
Communication expenses	3.20	2.78
Printing and stationery	4.51	5.47
Legal and professional fees *	13.22	10.09
Payment to auditors (refer note 26.2)	0.71	0.24
Bad debts written off (net)	15.74	0.55
Foreign exchange loss (net)	0.01	-
Loss allowance on trade receivables (net)	0.11	6.06
Loss (reversals) / allowance on other receivables (net)	(0.09)	0.40
Miscellaneous expenses	1.51	1.85
	<b>436.31</b>	<b>389.16</b>

\* Includes transaction with related parties (refer note 30)

26.1 Represents amounts incurred by the Company towards expenses relating to short-term leases, leases of low-value assets and ineligible GST on lease payments. Also refer note 2.2(f).

26.2 Payment to auditors \*\*

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Audit fees	0.71	0.21
Tax audit fee	-	0.03
	<b>0.71</b>	<b>0.24</b>

\*\*Amount inclusive of Goods and Service Tax (GST).

(This space has been intentionally left blank)



**Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**  
**Notes to the financial statements for the year ended March 31, 2025**

**27 Earnings per share (EPS)**

The following reflects the profit / (loss) and share data used in the basic and diluted EPS computations

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Net profit / (loss) for calculation of basic and diluted EPS attributable to the equity shareholders	113.47	(2.99)
Weighted average number of equity shares for calculating basic and diluted EPS *	14,57,05,440	14,57,05,440
Basic and diluted earnings per share (₹)	7.79	(0.21)

\* Includes CCDs to be converted into 76,923,000 (March 31, 2024: 76,923,000) equity shares. Refer note 12

**28 Segment information**

The Board of Directors of the Company has been identified as the Chief Operating Decision Maker (CODM) as defined by Ind AS 108, Operating Segments. The CODM evaluates the Company's performance and allocates resources based on an analysis of healthcare services in India.

The Company is primarily engaged in a single segment (business and geographical) i.e. healthcare services in India. As the Company's business activity primarily falls within a single business and geographical segment, there are no additional disclosures to be provided in terms of Ind AS 108 on 'Operating Segments'.

**29 Corporate Social Responsibility ('CSR') expenditure**

The Company is not required to spend any amount towards Corporate Social Responsibility as per Section 135 of the Act since there is no average profit in the preceding three financial years calculated as per provision of the Companies Act, 2013.

**30 Related party transactions**

(a) Names of related parties where control exists irrespective of whether transactions have occurred or not:

Holding Company	Manipal Hospitals Private Limited (w.e.f. September 20, 2023)
Ultimate holding company	Manipal Health Enterprises Private Limited (w.e.f. September 20, 2023)

(b) Names of other related parties as per Ind AS 24 with whom transactions have taken place during the year:

Promoters having significant influence over the Company (till September 20, 2023)	Diwakar Finvest Private Limited (till September 20, 2023) Suraj finvest Pvt Ltd (till September 20, 2023)
Fellow subsidiaries	- Manipal Hospitals (Bengaluru) Private Limited (w.e.f. September 20, 2023) - Manipal Hospitals (Dwarka) Private Limited (w.e.f. September 20, 2023) - Healthmap Diagnostics Private Limited (w.e.f. September 20, 2023) - Manipal Hospitals Synergie Private Limited ("MHSPL") (formerly known as Medica Synergie Private Limited) (w.e.f. July 01, 2024) - Manipal Hospitals Eastern India Private Limited ("MH East") (formerly known as Medica Hospitals Private Limited) (w.e.f. July 01, 2024) - Manipal Hospitals Bengal Private Limited (formerly known as North Bengal Clinic Private Limited) (w.e.f. July 1, 2024)
Other related parties (Enterprise under significant influence of ultimate holding company /holding company /promoters)	Emami Agrotech Ltd (till September 20, 2023) PAN Emami Cosmed Limited (formerly known as "Midkot Investments Private Limited") (till September 20, 2023) Premier Ferro Alloys & Securities Ltd (till September 20, 2023) Emami Frank Ross Ltd (till September 20, 2023) Nayee Deesha Communications Pvt Ltd (till September 20, 2023) Emami Art (Unit of Dev Infracity Pvt Ltd) (till September 20, 2023) Vishwa Jagriti Mission Trust (till September 20, 2023) Emami Foundation Charitable Clinic (till September 20, 2023) Doevee Commercials Ltd (till September 20, 2023) Ideal Dental Lab (till September 20, 2023) MEMG International India Private Limited (w.e.f. September 20, 2023) ManipalCigna Health Insurance Company Limited (w.e.f. September 20, 2023)

(c) Names of key management personnel as per Ind AS 24 irrespective of whether transactions have occurred or not:

Key Management Personnel	Mr. Rupak Barua, (Chief Executive Officer, till November 30, 2023) (Director, till September 20, 2023) Mr. Rajesh Pareek, Director (till September 20, 2023) Mr. Anil Malawat, Director (till September 20, 2023) Mr. Om Prakash Jhunjhunwala, Independent Director (till September 20, 2023) Ms. Karabi Sengupta, Independent Director (till September 20, 2023) Mr. Ashish Goenka, Director (till September 20, 2023) Mr. Mohan Kumar Bangalore Shankarappa, Independent Director (w.e.f. December 15, 2023, till February 21, 2024) Mr. Kapil Aggarwal, Independent Director (w.e.f. December 15, 2023, till February 21, 2024) Ms. Varsha Pande, Director (w.e.f. December 15, 2023, till February 21, 2024) Mr. Sameer Agarwal, Director (w.e.f. September 20, 2023) Dr. H. Sudarshan Ballal, Director (w.e.f. September 20, 2023) Mr. Karthik Rajagopal, Director (w.e.f. September 20, 2023)
--------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(d) Names of additional related parties as per Companies Act, 2013 with whom transactions have taken place during the year:

Company Secretary and Chief Financial Officer	Mr. Yogesh Manpuria (till February 15, 2024)
Company Secretary	Ms. Dolly Prasad (w.e.f. May 28, 2024)



Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)  
Notes to the financial statements for the year ended March 31, 2025

Transactions with the above related parties:

(₹ in crores)

Name of related party	Nature of transactions	March 31, 2025	March 31, 2024
AM Medical Centre Pvt Ltd	Income from medical service	-	0.77
Doevec Commercials Ltd	Interest Payment	-	0.50
Divakar Finvest Private Ltd	Commission Paid	-	0.16
	Interest Payment	-	25.25
Emami Agrotech Ltd	Commission Paid	-	1.59
Emami Art	Purchase of Snacks	-	0.04
	Painting	-	0.01
Emami Frank Ross Ltd	Purchase of medical items	-	33.82
Ideal Dental Lab	Purchase of Consumables	-	0.04
PAN Emami Cosmed Limited (formerly known as "Midkot Investments Private Limited")	Interest Payment	-	7.06
Nayee Deesha Communications Pvt Ltd	Advertisement	-	0.02
Premier Ferro Alloys Securities Ltd	Interest Payment	-	0.53
Suraj Finvest Private Ltd	Commission Paid	-	0.05
	Interest Payment	-	17.68
	Loan Repaid	-	10.75
Remuneration to key management personnel (KMP)	Short-term employee benefits ^	0.08	1.73
	Directors sitting fees	-	0.01
MEMG International India Private Limited	Royalty charges (included under legal and professional expense)	4.76	3.33
Manipal Hospitals (Dwarka) Private Limited	Reimbursement of expenses incurred on behalf of the Company	0.03	-
Manipal Hospitals Private Limited	Hospital services rendered	1.83	0.09
	Hospital services received	0.18	0.05
	Interest expense on ICD	3.82	1.62
	Repayment of interest on ICD	4.54	-
	Inter corporate deposits (ICD) received	314.90	-
	Inter corporate deposits (ICD) repaid	335.95	-
	Amount received from related party	0.68	-
	Amount paid to related party	0.02	-
	Purchase of medical pharmacies/consumables (net of returns)	0.04	-
	Sale of medical pharmacies/consumables (net of returns)	0.11	-
	Reimbursement of expenses incurred on behalf of the company	0.59	-
	Recovery of expense incurred on behalf of related party	0.29	-
Manipal Health Enterprises Private Limited	Recovery of expenses incurred on behalf related party	0.15	0.33
	Reimbursement of expenses incurred on behalf of the Company	143.00	-
	Amount paid to related party	143.59	-
	Amount received from related party	1.14	-
	Purchase of medical pharmacies/consumables (net of returns)	0.00*	-
ManipalCigna Health Insurance Company Limited	Insurance expenses	0.60	-
Manipal Hospitals (Bengaluru) Private Limited	Interest expense on ICD	1.17	-
	Inter corporate deposits (ICD) received	56.00	-
	Inter corporate deposits (ICD) repaid	56.00	-
	Repayment of interest on ICD	1.05	-
	Amount paid to related party	0.11	-
	Purchase of asset	0.11	-
Manipal Hospitals Synergie Private Limited (formerly known as Medica Synergie Private Limited)	Interest expense on ICD	0.90	-
	Inter corporate deposits (ICD) repaid	42.00	-
	Inter corporate deposits (ICD) received	45.00	-
Manipal Hospitals Eastern India Private Limited (formerly known as Medica Hospitals Private Limited)	Hospital services rendered	0.03	-
	Hospital services received	0.58	-
	Amount paid to related party	0.05	-
	Recovery of expense incurred on behalf of related party	0.02	-
	Sale of medical pharmacies/consumables (net of returns)	1.37	-

^ The remuneration to KMP does not include the provisions made with respect of gratuity and compensated absences, as they are determined on the Company as a whole

Balances receivable/payable by/to related parties are as follows:

(₹ in crores)

Name of related party	Nature of balances	March 31, 2025	March 31, 2024
MEMG International India Private Limited	Trade Payables	1.66	3.33
Manipal Hospitals (Dwarka) Private Limited	Other payables	0.03	-
ManipalCigna Health Insurance Company Limited	Other receivable	0.00*	-
Manipal Health Enterprises Private Limited	Other payables	0.74	0.33
Manipal Hospitals (Bengaluru) Private Limited	Other payables	0.00*	-
Manipal Hospitals Private Limited	Inter corporate deposit - availed	12.41	33.46
	Interest accrued on ICD	0.35	1.46
	Compulsory Convertible Debentures - ('CCD')	85.00	85.00
	Trade receivable	0.84	0.04
Manipal Hospitals Synergie Private Limited (formerly known as Medica Synergie Private Limited)	Inter corporate deposit - availed	3.00	-
	Interest accrued on ICD	0.81	-
Manipal Hospitals Eastern India Private Limited (formerly known as Medica Hospitals Private Limited)	Other receivable	0.89	-

\* Represents value less than ₹ 0.01 crore

Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year ended March 31, 2025 and March 31, 2024, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.



31 Employee benefit plan

(i) Defined contribution plan:

Amount recognised and included in note 23, 'Contribution to provident and other funds' in statement of profit and loss of ₹ 10.74 crores (March 31, 2024: ₹ 8.05 crores)

(ii) Defined benefit plan:

The Company has a defined benefit gratuity plan. Under this plan, every employees who are entitled as per the Gratuity Act, gets a gratuity on departure at 15 days of last drawn salary for each completed year of service. The scheme is funded.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and amounts recognized in the balance sheet

a) Statement of profit and loss and other comprehensive income

	(₹ in crores)	
	March 31, 2025	March 31, 2024
<b>i) Net employee benefit expense recognized in the statement of profit and loss</b>		
Current service cost	2.37	1.28
Past service cost	-	2.36
Interest cost on benefit obligation	0.98	0.54
<b>Net benefit expense charged to statement of profit and loss</b>	<b>3.35</b>	<b>4.18</b>

ii) Remeasurement

Return on Plan Assets, Excluding Interest Income	(0.12)	0.02
Actuarial changes arising from changes in financial assumptions	1.10	1.23
Actuarial changes arising from changes in demographic assumptions	(0.15)	1.59
Experience adjustments	1.07	0.36
<b>Total amount recognised in other comprehensive income</b>	<b>1.90</b>	<b>3.20</b>

b) Balance Sheet

Defined benefit obligation	17.93	14.76
Non current	-	-
Current	-	-
<b>Plan liability</b>	<b>17.93</b>	<b>14.76</b>

c) Change in projected benefit obligations

Defined benefit obligation at the beginning of the year	14.76	8.30
Fair value of plan asset at the beginning of the year	4.07	6.53
Current service cost	2.37	1.28
Past service cost	-	2.36
Interest cost	1.26	1.01
Benefits paid	(2.29)	(3.83)
Remeasurement of (Gain)/loss in other comprehensive income		
Actuarial (gain)/loss arising from change in financial assumptions	1.10	1.23
Actuarial (gain)/loss on account of demographic adjustments	(0.15)	1.59
Actuarial (gain)/loss on account of experience adjustments	1.07	0.36
Liabilities settled on account of intergroup transfer	(0.01)	-
Fair value of plan asset at the end of the year	<b>(4.25)</b>	<b>(4.07)</b>
<b>Obligations at end of the year</b>	<b>17.93</b>	<b>14.76</b>

d) Fair value of plan assets

Fair Value of Plan Assets at the Beginning of the year	4.07	6.53
Interest income	0.28	0.47
Contributions by the Employer	2.07	0.92
Benefit Paid	(2.29)	(3.83)
Return on Plan Assets, Excluding Interest Income	0.12	(0.02)
<b>Fair Value of Plan Assets at the end of the year</b>	<b>4.25</b>	<b>4.07</b>

e) Investment details of plan assets:

Insurer managed funds	4.25	4.07
<b>Total</b>	<b>4.25</b>	<b>4.07</b>

The Company expects to pay ₹ 2.00 crore in contributions to its defined benefit plans in 2025-26

f) The principal assumptions used in determining gratuity liability for the Company's plan are shown below:

Discount rate	6.55%	7.15%
Increase in compensation cost	6.00%	6.00%
Retirement age (years)	60 Years	60 Years
Employee turnover - for all age groups		

Age (Years)	Rate (p.a.)	Age (Years)	Rate (p.a.)
March 31, 2025	March 31, 2025	March 31, 2024	March 31, 2024
21 - 30	24.63%	21 - 30	34.00%
31 - 34	10.17%	31 - 40	18.00%
35 - 44	8.34%	41 - 50	7.00%
45 - 50	2.87%	51 - 59	8.00%
51 - 54	1.63%		
55 - 59	3.92%		

As per Indian Assured lives Mortality (2012-14) Ult (March 31, 2024: Indian Assured Lives Mortality (2012-14) Ult)

The estimates of future salary increases, considered in actuarial valuation take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.



**Sensitivity analysis**

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below:

	March 31, 2025		March 31, 2024	
	0.5% Increase	0.5% Decrease	0.5% Increase	0.5% Decrease
Discount rate	(4.12)%	4.43%	(3.06)%	3.23%
Future salary growth	4.43%	(4.16)%	3.25%	(3.10)%

**Maturity profile of defined benefit obligation:**

	₹ in crores	
	March 31, 2025	March 31, 2024
Within 1 year	1.62	2.31
Between 2 and 5 years	8.57	9.68
Between 6 and 10 years	8.05	7.38
Beyond 10 years	25.84	13.10

The average duration of the defined benefit plan obligation at the end of the reporting period is 8.54 years (March 31, 2024: 6.29 years).

**32 Capital and other commitments**

As at March 31, 2025, the Company has a commitment towards purchase of capital assets of ₹ 65.96 crores (March 31, 2024: ₹ 54.51 crores)

**33 Contingent liabilities**

**(33.1) Claims against the Company not acknowledged as debts**

Particulars	₹ in crores	
	March 31, 2025	March 31, 2024
<b>a) Claims against the company not acknowledged as debt</b>		
i) Patient Compensation (refer note 33.1.1)	14.63	151.95
ii) Indirect Tax Demand (refer note 33.1.2 and 33.1.3)	29.12	1.99
<b>b) Guarantees</b>		
(i) Bank Guarantee	4.49	3.98
	<b>48.25</b>	<b>157.92</b>

(33.1.1) These are the claims made against the Company in respect of various issues as described above. These cases are pending with various consumer dispute redressal and other forums. Based on the legal counsel views, the management does not expect these claims to succeed. Accordingly no provision for liability has been recognised in the Financial Statement.

(33.1.2) During the year ended March 31, 2024, Service Tax demand of ₹ 1.99 crores existed towards renting of immovable property and pending before Additional Commissioner, CGST & CX, Kolkata. The authority confirmed the aforesaid demand including interest and penalty. Aggrieved by the impugned order, the Company filed the appeal with Commissioner (Appeal-I).

(33.1.3) During the year ended March 31, 2025, the Company has received the demand order from Additional Commissioner for the period 2017-18 till 2021-22, wherein demand of ₹ 27.13 crores raised towards Non payment of GST on renting of immovable property. Aggrieved by the impugned order, the Company has filed a writ petition with the Hon'ble High Court of Kolkata.

The Company is confident that its position will be upheld for above Indirect tax litigations and accordingly the outcome of these will not have material effect on the Financial Statements. Pending resolution of the respective proceedings, it is not practicable for the Company to estimate the timings of cash outflows, if any, in respect of the above as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

(33.1.4) The Company along with MHPL, MHBPL, MHDPL and MHEPL have provided security to various lenders in the form of first ranking pari passu charge over Immovable properties including lease hold improvements, Movable Fixed Assets, Intangibles assets and Current Assets (as defined in the facility agreements) for the term loans amounting to ₹ 4,663.53 crore (March 31 2024: ₹ 3,883.13 crore) availed by the Company, MHPL, MHBPL, MHDPL, HCMCT (Silo), MHEPL and Manipal Hospitals Eastern India Private Limited ('MH Eastern').

(This space has been intentionally left blank)



34 Fair values & hierarchy

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices)

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair value

- The fair value of the quoted mutual funds are at Level 1 of Fair value hierarchy and are measured based on Net Asset Value (NAV) in active markets at the reporting date

- The fair value of the financial assets (other than mutual funds) and financial liabilities were based on amortised cost at the reporting date

The following table provides the fair values and fair value measurement hierarchy of financial assets and liabilities of the Company:

Quantitative disclosures fair value measurement hierarchy valued as at March 31, 2025:

March 31, 2025	Note No.	Level 1	Level 2	Level 3	Total
<b>Financial assets (at FVTPL)</b>					
Investments in mutual funds (quoted) (non-current)	4.1	34.06	-	-	34.06
Investments in mutual funds (quoted) (current)	9.1	0.04	-	-	0.04
		<b>34.10</b>	-	-	<b>34.10</b>

Quantitative disclosures fair value measurement hierarchy valued as at March 31, 2024:

March 31, 2024	Note No.	Level 1	Level 2	Level 3	Total
<b>Financial assets (at FVTPL)</b>					
Investments in mutual funds (quoted) (non-current)	4.1	29.58	-	-	29.58
Investments in mutual funds (quoted) (current)	9.1	11.48	-	-	11.48
		<b>41.06</b>	-	-	<b>41.06</b>

Set out below, is a comparison by class of the carrying amounts and fair value of the Company's financial instruments

Quantitative disclosures fair value measurement hierarchy as at March 31, 2025:

	Note	(₹ in crores)		
		FVTPL	Amortised Cost	Total
<b>Financial assets:</b>				
Investments in mutual funds (quoted) (non-current)	4.1	34.06	-	34.06
Investments in mutual funds (quoted) (current)	9.1	0.04	-	0.04
Trade receivables	9.2	-	91.66	91.66
Bank balances other than cash and cash equivalents	9.4	-	8.84	8.84
Cash and cash equivalents	9.3	-	14.01	14.01
Loans (current)	9.5	-	0.17	0.17
Other financial assets (current and non-current)	4,2,9,6	-	25.65	25.65
<b>Financial liabilities:</b>				
Borrowings (current and non-current)	14,1,16,1	-	1,783.33	1,783.33
Lease liabilities (current and non-current)	14.2	-	44.48	44.48
Trade payables	16.2	-	149.67	149.67
Other financial liabilities (current and non-current)	14,3,16,3	-	7.23	7.23
		-	<b>1,984.71</b>	<b>1,984.71</b>

Quantitative disclosures fair value measurement hierarchy as at March 31, 2024:

	Note	(₹ in crores)		
		FVTPL	Amortised Cost	Total
<b>Financial assets:</b>				
Investments in mutual funds (quoted) (non-current)	4.1	29.58	-	29.58
Investments in mutual funds (quoted) (current)	9.1	11.48	-	11.48
Trade receivables	9.2	-	100.21	100.21
Bank balances other than cash and cash equivalents	9.4	-	5.36	5.36
Cash and cash equivalents	9.3	-	48.32	48.32
Loans (current)	9.5	-	0.19	0.19
Other financial assets (current and non-current)	4,2,9,6	-	16.06	16.06
		<b>41.06</b>	<b>170.14</b>	<b>211.20</b>
<b>Financial liabilities:</b>				
Borrowings (includes current maturities of long-term borrowings)	14,1,16,1	-	1,733.46	1,733.46
Lease liabilities (current and non-current)	14.2	-	15.97	15.97
Trade payables	16.2	-	180.74	180.74
Other financial liabilities (current and non-current)	14,3,16,3	-	13.72	13.72
		-	<b>1,943.89</b>	<b>1,943.89</b>

All of the Company's financial assets and liabilities are carried at amortised cost except investment in mutual funds and are not under the Level 1 to 3 of the fair value hierarchy. Also, the Company does not have any financial assets and liabilities which are measured by way of FVTOCI. Further, there have been no transfers among Level 1, Level 2 and Level 3 during the current and previous years.

The management assessed that fair value of cash and cash equivalents, bank balances other than cash and cash equivalents, trade receivables, trade payables and other financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.



**35 Financial risk management**

The Company's principal financial liabilities, comprise term loans, lease liabilities, trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include investments, trade and other receivables, and cash and cash equivalents that are derived directly from its operations.

The Company's activities expose it to market risk, credit risk and liquidity risk. The Company's management oversees the management of these risk and works towards minimizing the potential adverse effects, if any, on its financial performance.

**A. Market risk**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises interest rate risk and currency rate risk. Financial instruments affected by market risk include borrowings, investments and deposits. The sensitivity analyses in the following sections relate to the position as at March 31, 2025 and March 31, 2024. The sensitivity of the relevant Profit and Loss item is the effect of the assumed changes in the respective market risks. This is based on the financial assets and financial liabilities held as of March 31, 2025 and March 31, 2024.

**(i) Interest rate risk**

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's debt obligations with floating interest rates in form of Term loans.

**Exposure to interest rate risk**

The interest rate profile of the Company's interest-bearing financial instruments are as follows:

	March 31, 2025	March 31, 2024
<b>Fixed rate instruments</b>		
<b>Financial asset</b>		
Margin money deposit with banks	13.60	6.37
Deposits with banks due to mature after twelve months from the reporting date	6.66	6.23
Deposits with banks original maturity with more than three months but less than twelve months	8.84	5.36
<b>Variable rate instruments</b>		
<b>Financial asset</b>		
Investments in mutual funds (quoted)	34.10	41.05
<b>Financial liability</b>		
Borrowings	1,783.33	1,733.46

**Sensitivity analysis for fixed rate instruments**

Based on the closing balance of fixed rate instruments, an increase/ decrease in interest rate by 1%, with all other variables remaining constant would result in increase/ decrease in interest income by ₹ 0.29 crores (year ended March 31, 2024: ₹ 0.17 crores).

**Sensitivity analysis for variable rate instruments**

Based on the closing balance of variable rate instruments, an increase/ decrease in interest rate by 1%, with all other variables remaining constant would result in increase/ decrease in interest cost by ₹ 17.49 crores (year ended March 31, 2024: ₹ 16.92 crores).

**B. Credit risk**

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its investing activities, including deposits with banks and financial institutions and other financial instruments.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables are monitored on a continuous basis by the management.

**(i) Trade receivables:**

The Company establishes an allowance for impairment that represents its estimate of expected losses in respect of trade receivables based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from trade receivables amounting to ₹ 91.66 crores (March 31, 2024: ₹ 100.21 crores). The movement in allowance for impairment in respect of trade receivables during the year was as follows:

	₹ in crores	
	March 31, 2025	March 31, 2024
<b>Allowance for credit loss</b>		
Opening balance	11.00	4.94
Loss allowance on trade receivables (net)	0.11	6.06
Closing balance	11.11	11.00

There is no significant concentration of credit risk and no single customer accounted for more than 10% of the revenue as of March 31, 2025 and March 31, 2024.



**Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**  
**Notes to the financial statements for the year ended March 31, 2025**

**(ii) Other receivables:**

The Company establishes an allowance for impairment that represents its estimate of expected losses in respect of other receivables based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from other receivables amounting to ₹ 2.12 crores (March 31, 2024: ₹ 0.68 crores). The movement in allowance for impairment in respect of other receivables during the year was as follows:

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Allowance for credit loss		
Loss (reversals) / allowance on other receivables (net)	(0.09)	0.40
Closing balance	0.35	0.44

**(iii) Financial instruments and deposits:**

Credit risk on cash and cash equivalents including fixed deposits is limited as the Company generally transacts with banks with high credit ratings assigned by international and domestic credit rating agencies. Investments of surplus funds, temporarily, are made only with approved counterparties, who meet the minimum threshold requirements under the counterparty risk assessment process.

**C. Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The table below summarises the maturity profile of the Company's financial liabilities based on contractual undiscounted payments:

	(₹ in crores)		
	March 31, 2025		
	Less than 1 year	More than 1 year	Total
Borrowings	156.14	2,720.38	2,876.51
Lease liabilities	10.20	45.14	55.34
Trade payables	149.67	-	149.67
Other financial liabilities	5.92	1.31	7.23

	(₹ in crores)		
	March 31, 2024		
	Less than 1 year	More than 1 year	Total
Borrowings	144.41	2,799.93	2,944.34
Lease liabilities	4.42	17.79	22.21
Trade payables	180.74	-	180.74
Other financial liabilities	12.08	1.64	13.72

(This space has been intentionally left blank)



**36 Capital management**

The primary objective of Company's capital management is to ensure that it maintains an optimum financing structure and healthy returns in order to support its business and maximize shareholder value

The Company manages its capital structure and makes adjustments, in light of the changes in economic conditions or business requirements

The Company monitors capital using a gearing ratio which is net debt divided by total equity plus net debt as shown below.

- Net debt includes borrowings (long term and short term), lease liabilities (long term and short term) less cash and cash equivalents, investment in mutual funds and
- Total equity comprises of issued share capital and all other equity components attributable to the equity share holder

	(₹ in crores)	
	March 31, 2025	March 31, 2024
Borrowings (including current maturities) (note 14.1 and 16.1)	1,783.33	1,733.46
Lease liabilities (note 14.2)	44.48	15.97
Less: cash and cash equivalents (note 9.3)	(14.01)	(48.32)
Less: Investment in mutual funds (quoted) (refer note 4.1 and 9.1)	(34.10)	(41.06)
<b>Net debt (A)</b>	<b>1,779.70</b>	<b>1,660.05</b>
Total equity attributable to the equity share holders of the Company	(567.93)	(679.98)
<b>Total capital (B)</b>	<b>(567.93)</b>	<b>(679.98)</b>
<b>Capital and net debt (C = A + B)</b>	<b>1,211.77</b>	<b>980.07</b>
<b>Gearing ratio (D = A / C)</b>	<b>147%</b>	<b>169%</b>

**37 Reconciliation of movements of liabilities to cash flows arising from financial liabilities**

Particulars	(₹ in crores)		
	Term loan	Inter-corporate deposits	Lease liability
Opening balance	1,700.00	33.46	15.97
Interest accrued on borrowings as on April 01, 2024	0.16	1.46	-
Additions during the year	68.00	415.90	33.62
<b>Cash flows including interest paid</b>			
- Principal payments / lease payments	(0.08)	(433.95)	(3.52)
- Interest expense	(139.94)	(6.18)	(1.95)
<b>Non-cash changes</b>			
- Lease liability reversal	-	-	(1.59)
- Interest expense	139.93	5.88	1.95
Interest accrued on borrowings as on March 31, 2025	(0.15)	(1.16)	-
<b>Closing balance</b>	<b>1,767.92</b>	<b>15.41</b>	<b>44.48</b>

Particulars	(₹ in crores)					
	Term loan from banks	Cash Credit from Banks	Inter-corporate deposits	Non-convertible debentures	Loan from related parties & others	Lease liability
Opening balance	748.60	38.26	-	53.35	897.03	7.31
Interest accrued on borrowings as on April 01, 2023	22.65	-	-	-	-	-
Additions during the year	1,700.00	-	33.46	-	-	11.49
<b>Cash flows including interest paid</b>						
- Principal payments / lease payments	(753.93)	(38.26)	-	(53.35)	(897.03)	(2.83)
- Interest expense	(137.90)	(1.51)	(0.16)	-	(38.86)	(1.04)
<b>Non-cash changes</b>						
- Interest expense	115.41	1.51	1.62	-	38.86	1.04
- Ind AS adjustment with respect to unamortised loan processing charges	5.33	-	-	-	-	-
Interest accrued on borrowings as on March 31, 2024	(0.16)	-	(1.46)	-	-	-
<b>Closing balance</b>	<b>1,700.00</b>	<b>-</b>	<b>33.46</b>	<b>-</b>	<b>-</b>	<b>15.97</b>

**38 Dues to Micro and Small Enterprises as per the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED):**

	March 31, 2025	March 31, 2024
(i) Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	3.55	4.53
(ii) Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	-	0.01
(iii) Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(iv) Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(v) Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(vi) Interest due and payable towards suppliers registered under MSMED Act, for payments already made	0.13	0.13
(vii) Further interest remaining due and payable for earlier years	-	-

**39** Due to the fire incident, the hospital building located at 15, Panchanantala Road, Kolkata- 700 029, the equipments, inventories and other assets installed therein had suffered massive damages. Inventories damaged by fire have been provided for in the books in earlier year. Other assets, having a written down value of ₹ 5.76 crores, are insured and the Company has lodged claims with the insurers. The Insurance Company has issued a voucher for full and final settlement of ₹ 5.41 crores against the claim made by the Company of ₹ 23.05 crores which was challenged by us and Arbitration clause invoked. However the Company has adjusted the claim of ₹ 5.41 crores against the respective heads in FY 2015-16. On 17.02.2019 the arbitration tribunal has given the award of ₹ 11.53 crores plus 9% interest p a from the date of commencement of arbitration proceeding, against our claim of ₹ 23.05 crores. We have filed a petition in Kolkata High Court challenging the award given by the arbitration tribunal

**40** The Company had, pursuant to the agreement dated January 01, 2007 with Murari Mohan Dass and Satrajit Ghosh Dass, agreed to purchase 33 Cottahs of land situated at 10/1, Panchanantala Road, 3F, Panchanantala Road, and 30 F, Gariahat Road, Kolkata -700029, P.S. Rabindrasarobar (Lake) from the landowner at a fixed price. However, the landowner refused to execute the sale deed on the agreed price and sought for enhancement of the purchase consideration. Subsequently, the landowner has filed a title suit against the Company. The Company also filed a specific performance of contract suit against the landowner before the Kolkata Alipore Court, and the matter is currently sub-judice.



#### 41 Accounting ratios

##### i) Current ratio

The current ratio is used to assess a company's short term liquidity. It is calculated by dividing the current assets by current liabilities.

##### ii) Debt-equity ratio

"Total debt" is defined as aggregate of non-current borrowings and current maturities of long term-borrowings and total equity includes issued capital and all other equity reserves.

##### iii) Debt service coverage ratio

The Debt Service Coverage Ratio (DSCR) measures the ability of a company to use its operating income to repay all its debt obligations, including repayment of principal and interest on both short-term and long-term debt. It is calculated by dividing net operating income by the total debt service (Interest and principal).

##### iv) Return on equity ratio

Equal to profit for the year divided by the equity during that period, and is expressed as a percentage.

##### v) Inventory turnover ratio

Inventory turnover indicates the rate at which a company sells and replaces its stock of goods during a particular period. The inventory turnover ratio formula is the cost of goods sold divided by the average inventory for the same period.

##### vi) Trade receivables turnover ratio

Accounts receivable turnover ratio is calculated by dividing revenue from operation by average accounts receivable. The ratio is used to measure how effective a company is at extending credits and collecting debts.

##### vii) Trade payables turnover ratio

This ratio is used to measure the number of times the business is paying off its creditors or suppliers in an accounting period. It is computed by dividing the total purchases by average accounts payable.

##### viii) Net capital turnover ratio

It is calculated by dividing annual sales by average stockholder equity (net worth). The ratio indicates how much a company could grow its current capital investment level.

##### ix) Net profit ratio

The net profit percentage is the ratio of after-tax profits to net sales. It reveals the remaining profit after all costs of production, administration, and financing have been deducted from sales, and income taxes recognized.

##### x) Return on capital employed

Return on Capital Employed is calculated by dividing our EBIT during a given period by Capital Employed (net worth, total debt and deferred tax liability) during that period.

##### xi) Return on investment

Return on investment (ROI) is a performance measure used to evaluate the efficiency or profitability of an investment or compare the efficiency of a number of different investments. To calculate ROI, the benefit (or return) of an investment is divided by the cost of the investment.

Ratio	Numerator	Denominator	As at March 31, 2025	As at March 31, 2024	% change	Reason for variance
i) Current ratio	Current assets	Current liabilities	0.73	0.91	-19%	NA
ii) Debt-equity ratio	Total debt	Total Equity	(3.14)	(2.55)	23%	NA
iii) Debt service coverage ratio	Earnings available for debt service= Net Profit after tax+ Non cash operating expenses+ Interest + Other adjustments like loss on sale of fixed assets, etc	Debt service= Interest & lease payments + Principal Repayments	2.23	0.12	1759%	On account of increase in the profitability of the company
iv) Return on equity ratio %	Net Profit after tax	Average Shareholders equity	18.19%	-0.44%	4233%	On account of increase in the profitability of the company
v) Inventory turnover ratio	Cost of Goods sold = opening inventory + purchases - closing inventory (medical and pharmacy consumables)	Average Inventory	14.89	17.71	-16%	NA
vi) Trade receivables turnover ratio	Revenue from operations	Average Accounts Receivable	11.85	10.54	12%	NA
vii) Trade payables turnover ratio	Total purchases	Average Trade Payables	1.76	1.91	-8%	NA
viii) Net capital turnover ratio	Net sales	Average Shareholders equity	(1.82)	(1.59)	15%	NA
ix) Net profit ratio %	Net Profit	Net Sales	9.98%	(0.28%)	3690%	On account of increase in the profitability of the company
x) Return on capital employed %	Earnings before interest and taxes	Capital Employed = Net Worth + Total Debt + Deferred Tax Liability	14.07%	15.55%	10%	NA
xi) Return on investment %	Interest (Finance Income)	Investment	5.43%	5.29%	3%	NA




**42 Other Statutory Information**

- (i) The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (ii) The Company do not have any transactions with companies struck off.
- (iii) The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (iv) The Company is in compliance with number of layers of companies, as prescribed under clause (87) of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.
- (v) The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (vi) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vii) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (viii) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961
- (ix) The Company has not been declared wilful defaulter by any bank or financial institution or other lender.

As per our report of even date attached

**For B S R & Co. LLP**

Chartered Accountants  
Firm Registration number 101248W/W - 100022


  
Siddhartha Sharma  
Partner  
Membership number: 118756


Place: Bengaluru  
Date: May 27, 2025

**For and on behalf of the Board of Directors of**

**Manipal Hospitals (East) India Private Limited (formerly known as AMRI  
Hospitals Private Limited and AMRI Hospitals Limited)**

  
Anurag Agarwal  
Director  
DIN: 07554053

  
Dr. H. Sudarshan Ballal  
Director  
DIN: 01195055

  
Dolly Prasad  
Company Secretary  
Membership No. A49842

Place: Bengaluru  
Date: May 27, 2025